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Abstract 
 
Cholera toxin consists of one A subunit (CTA) and five B subunits (CTB). CTA contains the 
toxic domain CTA1 as well as a short sequence CTA2. Toxic CTA1 is responsible for the 
symptoms of cholera toxin. CTA2 serves to link A subunit noncovalently to B subunit by fitting 
part of itself within the central pore formed by CTB pentamer. CTB mediates the binding of the 
holotoxin to GM1 ganglioside receptors on mucosal epithelia.  
It was elucidated that B subunit was very useful as an adjuvant and carrier to increase the 
immunogenicity of vaccines and antigens coupled to it. In addition, a novel strategy to construct 
the holotoxin-like complex consisting of antigen peptide-CTA2 and pentameric CTB, is also 
attractive. This strategy utilized CTB as a transporter for the effective delivery of vaccines and 
antigens with reduced toxicity and high efficacy.  
All these confer CTB a bright prospect as a vehicle to facilitate the induction of mucosal 
immune responses for a broad range of vaccines and antigens for human purposes. 
 
Part I 
Utilization of CTB as an adjuvant and carrier:  
Expression of recombinant antigens of Japanese cedar pollen allergen T cell epitopes fused 
with CTB in Bacillus subtilis, aiming at the treatment of Japanese cedar pollinosis 
 
Peptides only containing T cell epitopes from allergens, which are not reactive to the 
allergen-specific IgE, are appropriate candidates as antigens for the prevention and treatment of 
allergy. As many T cell epitopes from allergens as possible should be included to achieve 
sufficient efficacy in a large population of allergic patients. Japanese cedar (Cryptomeria 
japonica) pollen is one of the most prevalent allergens in Japan. Two major allergenic proteins 
of the pollen, Cry j1 and Cry j2, have been isolated and characterized. In the study, up to five 
major T cell epitopes from Cry j1 and seven from Cry j2 were selected on the basis of 
references. To utilize the ability of CTB as the adjuvant and carrier, genes encoding epitopes 
from Cry j1 or Cry j2 were fused to CTB gene in tandem by PCR, to construct two fusion genes, 
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ctb-cry j1 epi and ctb-cry j2 epi. The fusion genes were expressed firstly in E. coli. The 
expressed CTB-Cry j1 epi and CTB-Cry j2 epi were purified to a high homogeneity with 
Ni-NTA resin, giving about 11 and 18 mg/L culture of purified proteins, respectively. Results of 
antigenic reactivity by western blotting showed that recombinant CTB-Cry j1 epi or CTB-Cry j2 
epi was recognized specifically by anti-cholera toxin as well as anti-Cry j1 (or anti-Cry j2) 
antibodies. It was found that Cry j1 epi and Cry j2 epi could not be expressed without CTB 
fused to them, indicating that CTB also functioned to stabilize short epitopes expressed in 
bacteria-based systems.  
A traditional Japanese food, natto, is an ideal food carrier for edible antigens and vaccines, 
especially for the treatment of Japanese cedar pollinosis, because it is made easily and full of 
nutrients, and most importantly, is the favorite food of Japanese people. Natto is made from 
soybeans fermented by a bacterium classified as Bacillus subtilis (natto). Analysis of genome 
showed the structure of B. subtilis (natto) strain was similar to that of Bacillus subtilis. It was 
demonstrated that repeated transformation of a B. subtilis strain with genomic DNA from B. 
subtilis (natto) conferred B. subtilis the ability to ferment natto. On the other hand, the 
non-cognate DNA fragment can be accommodated in the genome of B. subtilis through 
homologous recombination of pBR322-derived sequences artificially integrated in the B. 
subtilis genome. Therefore, natto fermented by the hybrid B. subtilis containing the antigen 
gene in its genome becomes a therapeutic agent of the allergy.  
In the study, in order to try to express the antigen in B. subtilis, the gene of ctb-cry j1 epi was 
firstly inserted in the vector pHASH120 which contains E. coli plasmid pBR322-derived 
sequences. The constructed plasmid was named as pHASH120-ctb-cry j1 epi. The 
pBR322-derived sequences were also preinstalled in the genomic leuB locus of B. subtilis strain 
168 trpC2 to construct B. subtilis strain BEST2131. BEST2131 accepted the gene of ctb-cry j1 
epi by homologous recombination after being transformed by the constructed plasmid. Although 
results revealed the successful insertion of ctb-cry j1 epi in the genome of BEST2131, the 
expression of CTB-Cry j1 epi from ctb-cry j1 epi gene in the genome of BEST2131 was not 
detected. To verify whether the antigen gene is functional or not, a multi-copy plasmid 
pGETS103 with the full length of pBR322 was utilized to recover ctb-cry j1 epi from the 
genome of BEST2131. The resultant pGETS103 containing ctb-cry j1 epi was employed to 
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transform B. subtilis 168 trpC2, which does not possess pBR322-derived gene, and thus no 
homologous recombination happens between the plasmid and the genome. The transformant 
was shown to produce much quantity of the antigen peptide. This indicated that the recovered 
antigen gene was functional in the plasmid and the antigen protein was successfully expressed 
in B. subtilits. It was assumed that the undetectable expression of the antigen peptide from the 
gene in the genome might be due to: (1) single copy number of the antigen gene in the genome; 
(2) some unknown factors in the genome which affected the nomal expression of the inserted 
gene; (3) insufficient sensitivity and specificity of western blotting to detect antigen protein if 
there was expression.  
Middile wall protein (MWP) promoters from Bacillus brevis 47 are stronger promoters for 
the transcription of mRNA, therefore the stronger expression of proteins. However, even if 
MWP promoters were used as the promotor of the antigen gene, also no detection of the antigen 
peptide in the genome was available. Complex factors in the genome for the expression of the 
foreign protein should be investigated.  
 
Part II 
Utilization of CTB as a transporter: 
Expression of pentameric CTB and an attempt of the assembly of holotoxin-like complex 
in a cell-free system  
 
A new strategy for the delivery of antigens is to co-express CTB and the interested peptide or 
protein linked to the nontoxic CTA2 segment to create a holotoxin-like chimera. This generates 
CT-based mucosal vaccines or antigens with reduced toxicity and high efficiency. However, to 
our knowledge, the recombinant CTB expressed in E. coli was in an insoluble form, therefore 
impossible to assemble holotoxin-like complex. The only in vitro assembly method involved 
denaturation and renaturation of CTA2-fusion protein and CTB, which was troublesome and 
actually difficult for the practical application. The cell-free system can provide the platform to 
assemble the holotoxin-like complex by co-expressing CTB and the fusion protein of interested 
peptide or protein linked to CTA2 simultaneously. However, before the assembly of the 
holotoxin-like complex is carried out, the ability of CTB to form the pentamer has to be 
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verified.  
Results showed that pentameric CTB was little expressed in E. coli, but was expressed in the 
cell-free system easily and steadily. This indicated that the cell-free system was a valuable tool 
and platform for the expression of structurally complex oligomeric proteins.  
An attempt to assemble cholera toxin-like complex by co-expressing CTB and the fusion 
protein of green fluorescence protein (GFP) linked to CTA2 in the cell-free system was 
performed. Results revealed no formation of complex. It was presumed that the incomplete 
expression of GFP-CTA2 or burying of hydrophobic CTA2 inside the hydrophobic region of the 
cylindrical structure of GFP, might result in the failure of the interaction between CTA2 and 
CTB, thus the formation of holotoxin-like complex. SDS-PAGE results proved the interaction 
between the segments of GFP and CTA2 in GFP-CTA2, although the kind of interaction 
remained unknown. More stable and/or more hydrophilic proteins or a flexible linker between 
GFP and CTA2 are expected to be workable. The functional chaperones may facilitate and/or 
stabilize the formation of complex.  
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Chapter 1 
 
General introduction  
 
Cholera toxin (CT) is an oligomeric protein with the molecular weight of 84,000 daltons and 
consists of a single A subunit (CTA) surrounded by five B subunits (CTB). CTA contains the 
toxic domain (CTA1) as well as a short sequence (CTA2). CTA2 serves to link A subunit 
noncovalently to B subunit by fitting part of itself within the central pore formed by CTB 
pentamer [1]. The schematic structure of cholera toxin is shown in Figure 1.1. 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic structure of cholera toxin 
 (http://www.rcsb.org/pdb/smartSubquery.do?smartSearchSubtype=TreeQuery&t=11&n=56411) 
 
CT is a potent activator of adenylate cyclase and pathogenic agent responsible for the 
symptoms of cholera. The action mechanism of cholera toxin is shown in Figure 1.2. When 
cholera toxin is released from the bacteria in the infected intestine, it binds to the intestinal cells 
known as enterocytes through the interaction of the pentameric B subunit of the toxin with the 
GM1 ganglioside receptor on the intestinal cell, triggering endocytosis of the toxin. 
Subsequently, the A/B cholera toxin must undergo cleavage of the A1 domain from the A2 
domain in order for A1 to become an active enzyme, i.e. ADP-ribosyltransferase. Once inside 
the enterocyte, the enzymatic A1 fragment of the toxin A subunit enters the cytosol, where it 
activates the G protein Gs through an ADP-ribosylation reaction that acts to lock the G protein 
CTB pentamer 
CTA2  
CTA1  
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in its GTP-bound form, thereby continually stimulating adenylate cyclase to produce cAMP. 
The high cAMP levels activate the cystic fibrosis transmembrane conductance regulator (CFTR), 
causing a dramatic efflux of ions and water from infected enterocytes, leading to watery 
diarrhoea. 
 
 
 
Figure 1.2 Action mechanism of cholera toxin 
(http://www.ebi.ac.uk/interpro/potm/2005_9/Page2.htm) 
 
Cholera toxin has become a powerful research tool not only in microbiology, but in the fields 
of physiology, cell biology and biochemistry, as well. Cholera toxin has several 
immunomodulating effects which alone or in combination might explain its strong adjuvant 
properties in stimulating immune responses to admixed unrelated antigens and the subsequent 
appearance of corresponding mucosal IgA after oral immunization, although the mechanism 
underlying it remains unclear. CTB is an effective oral immunizing agent, which in a large field 
trial has been shown to afford protection against both cholera and enterotoxigenic E. coli-caused 
diarrhea. This has made CTB as such an important component, together with killed whole 
vibrios, of an oral cholera vaccine [2]. Moreover, CTB has attracted much interest rescently as 
an an adjuvant and immunogenic carrier for various other peptide antigens admixed or coupled 
to it, despite some researchers thought the coadministration of a little CTA was needed. Much 
progress has been made in preparing immunogenic hybrid antigens by coupling them 
chemically or genetically to CTB [3-6]. Indeed, in several systems, oral administration of such 
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hybrid antigens has been found to markedly potentiate both intestinal and extraintestinal IgA 
immune responses against the CTB-coupled antigens and also to elicit substantial circulating 
antibody responses. Therefore, CTB as an adjuvant and carrier is useful to improve the mucosal 
immunogenicity of antigens. It was also found that CTA2 domain itself was necessary and 
sufficient to enable peptides linked to the N-terminus of CTA2 to form stable holotoxin-like 
chimeras [7]. Thus, the construction of holotoxin-like complexes, utilizing CTB as a transporter 
for the effective delivery of antigens, is also desirable. This strategy provides the bright prospect 
for generating CT-based mucosal vaccines and antigens with reduced toxicity and high efficacy.  
In summary, all these give promise for the use of CTB as vehicles to facilitate the induction 
of mucosal immune responses to a broad range of antigens for human vaccination purposes. 
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Chapter 2 
 
Utilization of CTB as an adjuvant and carrier for oral delivery of antigen 
peptides: 
Expression of recombinant antigens of Japanese cedar pollen allergen T cell 
epitopes fused with CTB in Bacillus subtilis, aiming at the treatment of 
Japanese cedar pollinosis 
 
 
2.1 Introduction 
 
One of promising approaches to the prevention and treatment of allergy is desensitization by 
vaccination with peptides which are derived from allergens. To avoid allergic reactions due to 
the presence of allergen-specific IgE binding sites in the whole antigen, the novel antigen 
lacking the epitopes reactive to IgE should be utilized. Peptides only containing T cell epitopes 
from allergens are appropriate candidates as antigens. Whereas, a major difficulty with this 
approach is the diversity of MHC class II molecules in individuals, resulting in patients with 
different MHC class II molecules responding to different allergen-derived peptides [8]. 
Therefore, as many T cell epitopes of allergens as possible should be included to achieve 
sufficient efficacy in a large population of allergic patients [9]. Japanese cedar pollen, produced 
largely in spring, is one of the most prevalent allergens in Japan. Japanese cedar pollinosis has 
become a national disease in Japan, with more than 10% of the population suffering from it [10]. 
Two major allergenic proteins of the pollen, Cry j1 and Cry j2, have been isolated and 
characterized [11-13]. Recombinant peptides, in which multiple T-cell epitopes from Japanese 
cedar allergenic proteins were linked, have been developed, and basic immunologic studies have 
exhibited their potency as immunotherapeutic agents [9, 14, 15]. However, not many T cell 
epitopes of Cry j1 and Cry j2 were included in the developing and developed 
immunotherapeutic peptides. In the study, much more epitopes, i.e. five major T-cell epitopes 
from Cry j1 and seven from Cry j2 were selected on the basis of references [9, 14]. 
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Much progress has been made in the utilization of non-toxic cholera toxin B subunit (CTB) as 
an adjuvant and antigen-carrier system to enhance the mucosal immune response to various 
foreign antigens chemically or genetically coupled to it. In the study, genes encoding epitopes 
from Cry j1 or Cry j2 were fused to CTB gene in tandem by PCR, to construct two fusion genes, 
ctb-cry j1 epi and ctb-cry j2 epi.  
Edible vaccines and antigens do not accompany the torment by repeated injections and the 
refrigeration is not needed for storage. Particularly, the availability of vaccines and antigens at a 
reasonable cost by the mass production is valuable for developing countries. Thus, the 
development of edible vaccines and antigens is very attractive. The expression of vaccines and 
antigens in plants (such as potato, rice and etc), algae and edible bacteria (such as Bacillus 
subtilis) is practical in obtaining the mass production of edible vaccines and antigens. Recently, 
plantation of transgenic rice preventing Japanese cedar pollinosis is being under plan in Japan. 
However, the possibility of gene diffusion to surrounding plants by pollination limits the 
application of vaccine or antigen-producing transgenic plants. Edible bacteria and algae are 
outstanding with advantages such as easy cultivation and short harvest period. A traditional 
Japanese food, natto, was fermented from soybeans by the bacterium named as B. subtilis 
(natto). Natto is an ideal food carrier for edible antigens and vaccines, especially for the 
treatment of Japanese cedar pollinosis, because it is easily made and full of nutrients and can be 
stored with the fungicidal antibiotics produced by the natto-producing bacterium, and most 
importantly, is the favorite food of Japanese people.  
B. subtilis (natto) is classified as closely related strain to B. subtilis strain 168 trpC2, which is 
the best-characterized gram-positive bacterium [16]. Analysis of genomic structure showed the 
structure of B. subtilis (natto) was roughly 98% similar to that of B. subtilis 168 trpC2 and the 
only 2% difference might account for their biochemical divergence [17, 18]. Extensive 
biochemical and genetic studies at a molecular level have not been conducted on the genes and 
enzymes involved in the fermentation of natto [19-23], although the genes required for a natto 
production bioprocess have been yet to be totally clarified. A limited number of genetically and 
biochemically characterized gene homologues, including psgABCD involved in the synthesis of 
γ-PGA, iep involved in the regulation of protease secretion, and glr and yrpC involved in the 
racemization of glutamate, are also present in the genome of B. subtilis 168 trpC2. However, B. 
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subtilis 168 trpC2 does not produce capsular PGA, suggesting that highly coordinated 
regulation of gene expression, as well as physiological conditions during growth on the soybean 
surface, are required for good natto producers. The gene regulation of natto fermentation can 
function in B. subtilis 168 trpC2 if the relevant genes are appropriately transferred to 
corresponding loci of the genome via homologous recombination by repeated transformation of 
B. subtili 168 trpC2 with the genomic DNA from B. subtilis (natto) [17]. As more DNA 
sequence from the natto strain was transferred to the recipient B. subtilis 168 trpC2 strain, the 
natto fermentation ability was gradually enhanced in proportion to the amount of the natto 
strain-derived DNA. It was found that the assembly of >300kb segments from B. subtilis (natto) 
in the genome of B. subtilis 168 trpC2 converted the strain 168 trpC2 to a natto producer [24, 
25].  
B. subtilis 168 trpC2, has several genetic features that distinguish it from the well-known 
gram-negative E. coli, and has historically been used as a recipient for horizontal transfer of 
genes due to its ability to develop competency [26]. To circumvent the potential obstacles 
accompanying the use of plasmid vectors, i.e. variable copy number per cell and genetic 
instability, the creation of strains carrying interested gene sequence stably maintained in the B. 
subtilis genome is an alternative strategy. The non-cognate DNA can be inserted in the genome 
of B. subtilis by homologous recombination, which happens between two homologous DNA 
segments, one in the chromosome and the other in the plasmid containing the interested gene. 
pBR322 has many advantages as an artificially integrated sequence in the B. subtilis genome for 
the homologous recombination [26]: (1) its entire nucleotide sequence has been determined; (2) 
its replication profile in E. coli has been well established; (3) it does not replicate autonomously 
in B. subtilis; (4) two marker genes for E. coli, the β-lactamase gene (amplicillin resistance) and 
the tetracycline resistance determinant gene (tetracycline resistance) are inert in B. subtilis; (5) 
several useful restriction enzyme sites are availabe; (6) it has a low copy number in E. coli 
(15-20 copies per cell); and (7) a cosmid vector pHC79, frequently used to clone large DNA 
segments, has a structure identical to that of pBR322 except for the cos sequence at the PvuII 
site. The integrated pBR322 sequence in the genome of B. subtilis can replicate as part of the 
chromosome and is used to accommodate the non-cognate DNA fragment.  
A novel vector, named as pHASH120, was constructed by Ohashi et al [27]. Features of the 
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vector can be summarized as follows: (1) a promoter amplified by PCR can be introduced to the 
vector directly with the TA-cloning method; (b) an open reading frame (ORF) amplified by 
PCR can be oriented downstream of the promoter and RBS at an optimized distance; and (3) the 
newly constructed gene in E. coli is directly cloned into the B. subtilis genome as a single copy. 
The interested gene together with the promoter and RBS between the pBR322-derived 
sequences in the recombinant pHASH120 can be integrated into the genome of B. subtilis via 
pBR322 sequences carried by B. subtilis by homologous recombination. The vector uses the 
promoter and RBS optimal for B. subtilis, so optimal expression of inserted non-cognate DNA 
in the genome of B. subtilis is expected. Moreover, because the integrated DNA at the genomic 
pBR locus can be tranferred to a muti-copy plasmid pGETS103 by a recombinational 
tranformation procedure, the copy number of the cloned genes can be increased immediately.  
In summary, the antigen gene inserted in pHASH120 can be inserted in the genome of B. 
subtilis by homologous recombination. The resultant B. subtilis with the antigen gene in the 
genome can obtain the ability in the fermentation of natto by repeated transformations with the 
genomic DNA of B. subtilis (natto), thus available for the preparation of edible antigen. The 
scheme about the preparation of edible antigen using natto as the food carrier is shown in Figure 
2.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Scheme about the preparation of edible antigen using natto as the food carrier 
 
 Vector containing antigen gene 
 
B. subtilis 
(with competency in transformation,  
but unable to ferment natto ) 
 
B. subtilis (natto) 
(able to ferment natto, but without 
competency in transformation) 
B. subtilis (natto) genomic DNA 
Repeated transformation 
 
B. subtilis (natsuko) 
(with both abilities in competency of 
transformation and fermention of natto)
Extraction of 
genomic DNA 
Integration of 
antigen gene in 
B. subtilis genome Hybrid bacteria 
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2.2 Materials and methods 
 
2.2.1 Bacterial strains, plasmids and media 
 
Plasmids and bacterial strains used in the study are listed in Table 2.1, respectively. 
Recombinant plasmids of pUC18 and pET28a (Novagen) were amplified using E. coli strain 
JM109 (Takara) as the host, and ampicillin (100µg/ml) and kanamycin (25µg/ml) were used as 
the selection antibiotics respectively. E. coli strain BL21 (DE3) (Novagen) was used for the 
expression of antigen peptides.  
B. subtilis strains, including B. subtilis 168 trpC2 and B. subtilis BEST2131, and plasmids, 
including pHASH120 and pGETS103 which are related to amplification and expression of the 
antigen gene in B. subtilis, were kindly gifted by Dr. Mitsuhiro Itaya of Mitsubishi Kagaku 
Institute of Life Sciences, Tokyo. BEST2131 was constructed from 168 trpC2 (original strain), 
with the insertion of pBR322 sequences in the leuB gene (leuB::pBRTc) of 168 trpC2 [26] and 
becomes resistant to tetracycline. E. coli strain DH5α (Takara) was used for amplification of 
recombinant plasmids of pHASH120 and pGETS103. To select positive transformants, 50µg/ml 
of ampicillin, 5µg/ml of chloramphenicol, 10µg/ml of tetracycline, and 250µg/ml of blasticidin 
S were used.  
All the antibiotics were purchased from Wako, except ampicillin which was purchased from 
Sigma. E. coli and B. subtilis were grown at 37℃ in LB medium.  
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Table 2.1 Plasmids and bacterial strains used in the study 
* Antibiotics indicated are: Amp, ampicillin; Kana, kanamycin; Cm, chloramphenicol; Tc, tetracycline; Bs, blasticidin 
S.   R and S refer to “resistant” and “sensitive”, respectively.   
 
Plasmid (kb) Description Bacterial strain Antibiotic resistance* Purpose 
pUC18 (2.7) - JM109 AmpR Cloning 
pUC18- 
ctb-cry j1 epi (3.2) 
Containing  
ctb-cry j1 epi 
JM109 AmpR Cloning 
pUC18- 
ctb-cry j2 epi (3.3) 
Containing 
ctb-cry j2 epi 
JM109 AmpR Cloning 
pET28a (5.4) - JM109 KanaR Cloning 
JM109 KanaR Cloning  pET28a- 
ctb-cry j1 epi (5.9) 
Containing 
ctb-cry j1 epi BL21 (DE3) KanaR Expression of antigen 
JM109 KanaR Cloning  pET28a- 
ctb-cry j2 epi (5.9) 
Containing 
ctb-cry j2 epi BL21 (DE3) KanaR Expression of antigen 
DH5α BsR, AmpR and CmR Cloning 
pHASH120 (5.8) 
Containing 
PS10-RBS 
B. subtilis 
BEST20038 
TcS, BsS and CmR 
Negative control  
for antigen expression 
DH5α BsR, AmpR and CmR Cloning 
pHASH120- 
ctb-cry j1 epi (6.3)  
Containing 
PS10-RBS- 
ctb-cry j1 epi 
B. subtilis 
BEST2131 
TcS, BsS and CmR 
Integration of PS10-RBS-ctb-cry 
j1 epi in leuB loci of genome 
pGETS103 (14.5) 
Shuttle vector 
of E. coli and  
B. subtilis  
DH5α AmpR and TcR  Cloning 
Hind III digested 
pGETS103 (14.5) 
Unable to 
self-replicate 
in B. subtilis 
B. subtilis 
BEST2131- 
ctb-cry j1 epi 
TcR and CmR 
Recovery of antigen gene from 
genome to multi-copy plasmid 
DH5α CmR Cloning 
pGETS103- 
ctb-cry j1 epi (15.0) 
Containing 
PS10-RBS- 
ctb-cry j1 epi 
B. subtilis  
168 trpC2 
TcR and CmR 
Investigation of antigen  
expression in multi-copy plasmid 
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2.2.2 Selection of major T cell epitopes from Cry j1 and Cry j2 
 
On the basis of references, major T cell epitopes from Cry j1 and Cry j2 were selected. 
Selection based on considerations that epitopes should be able to stimulate strong proliferative 
response of T cell line which is Cry j1 or Cry j2-specific, and various MHC class II types, the 
molecules of which are capable of presenting T cell epitopes, should be included to obtain 
reliable applicability in a large population of patients.  
 
2.2.3 Construction of fusion genes  
 
Fusion genes of ctb-cry j1 epi and ctb-cry j2 epi were acquired by stepwise PCR: ctb was 
used as the template of the first PCR and the resultant PCR product was used as the template of 
the next reaction, and other reactions were performed in the same way. The forward primer 
(5’actgcggatccacacctcaaaatattactg3’, the sequence indicated in bold is the BamHI site, and the 
sequence written in red characters is complementary to the beginning coding sequence of ctb) 
was designed to give rise to the BamHI site at the 5’ end. The reverse primer from P1-P5 or 
P’1-P’7 possesses an overlapping sequence homologous to the template and an overhang of 
the epitope gene which was devised based on the codon usage in E. coli.. Sequences and the 
reaction order of reverse primers are listed in Table 2.2 and 2.3. Since it is difficult and costly to 
synthesize the primer having long gene sequence of peptide such as Cry j1-106-125, Cry 
j2-191-209 or Cry j2-345-374, these genes were divided into two separate primers. Finally, the 
reverse primer of Cry j1-212-224-Hind III (5’gcgtcaagcttcgggccgaactggttgaac3’, the sequence 
indicated in bold is the Hind III site, and the sequence written in red characters is 
complementary to the template) or Cry j2-345-374-2-Hind III (5’gctgaaagcttgaaatagccgttcgcgtt 
a3’, the sequence indicated in bold is the Hind III site, and the sequence written in red 
characters is complementary to the template) was used to produce the Hind III site at the 3’ end 
of the fusion gene of ctb-cry j1 epi or ctb-cry j2 epi.  
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Table 2.2 Reverse primers used to construct the fusion gene of ctb-cry j1 epi 
* The sequence writtren in red characters is complementary to the template.  
 
Table 2.3 Reverse primers used to construct the fusion gene of ctb-cry j2 epi 
Name Position in Cry j2 antigen Sequence* (5’-3’) 
P’1 Cry j2-77-89 tttccagctcgccgggttctgatacgccgcaataatgccatttgccatactaattgcgg  
P’2 Cry j2-96-107 gcccatcagcgtgaagcccgtcagtttcgcgaactgtttccagctcgccgggttct  
P’3 Cry j2-191-209-1 atggaagtttttgctcgcgaaaatatcaatgcccatcagcgtgaagcccg  
P’4 Cry j2-191-209-2 gcccgtgccaatcgtgtttttctgcagatggaagtttttgctcgcga  
P’ 5 Cry j2-245-259 gaatttcgcgccgttcacatgcacatagctcacttccgcacggctgcccgtgccaatcgt  
P’6 Cry j2-345-374-1 gctcgtcagtttcaggctaatatcgctcagtttaatatctttgcagaatttcgcgccgtt  
P’7 Cry j2-345-374-2 gaaatagccgttcgcgttatcgttcaggcagctcgcaattttgccgctcgtcagtttcag  
* The sequence writtren in red characters is complementary to the template.  
 
All primers were purchased from Proligo. PCR was accomplished with high fidelity KOD 
DNA polymerase (Toyobo). PCR reaction conditions were as follows: 98℃, 5min preheating, 
followed by 25 cycles of denaturing (98℃, 15sec), annealing (65℃, 2sec) and elongation (74℃, 
30sec). After each step of PCR, the product was purified using PCR Purification Kit (Qiagen) or 
purified from the agarose (Takara) gel using Gel Extraction Kit (Qiagen) according to 
manufacturers’ instructions. PCR products were analyzed on the 2% agarose gel stained with 
ethidium bromide by electrophoresis.  
 
 
Name Position in Cry j1 antigen Sequence* (5’-3’) 
P1 Cry j1-16-30 gctgccgaagcccaccgcgcaatccgccagtttcatacggttctgatttgccatactaattgcgg 
P2 Cry j1-81-95 acggccatcgaacgttttatagcccgcaatatacatcggcattttgctgccgaagcccac  
P3 Cry j1-106-125-1 gttgctcacacgtttaatgaacacgcacggacggccatcgaacgttttat  
P4 Cry j1-106-125-2 gccatacagatgcaggccatgaataatcacgttgctcacacgtttaatga  
P5 Cry j1-212-224 cgggccgaactggttgaacgccaccgtcactttcatgctgccatacagatgcaggccat  
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2.2.4 Construction of recombinant plasmids for E. coli  
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Structure and cloning/expression region of E.coli plasmid pET28a 
(http://www.genomex.com/vector_maps/pET28_map.pdf) 
 
The resultant DNA fragments of ctb-cry j1 epi and ctb-cry j2 epi from PCR were digested 
with BamHI and Hind III restriction enzymes (Takara) and cloned into corresponding sites of 
pUC18 plasmid to produce recombinant cloning plasmids of pUC18-ctb-cry j1 epi and 
pUC18-ctb-cry j2 epi. E. coli JM109 competent cells were transformed with the recombinant 
cloning plasmids, and positive colonies were selected from LB/ampicillin plates. Inserts were 
digested out of extracted plasmids with BamHI and Hind III restriction enzymes, and then 
BglII              T7 promoter        Lac operator       XbaI                RBS 
agatctcgatcccgcgaaattaatacgactcactataggggaattgtgagcggataacaattcccctctagaaataattttgtttaactttaagaaggagata 
  NcoI           His×6 tag                thrombin     NdeI NheI      T7 tag 
taccatgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccatatggctagcatgactggtggacagcaaatgggt 
   BamHIEcoRISacI  SalI HindIII NotI   XhoI    His×6 tag 
cgcggatccgaattcgagctccgtcgacaagcttgcggccgcactcgagcaccaccaccaccaccactgagatccggctgctaacaaagcccgaaag 
                     Bpu1102I                T7 terminator 
gaagctgagttggctgctgccaccgctgagcaataactagcataaccccttggggcctctaaacgggtcttgaggggttttttg 
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cloned into pET28a plasmid, which provides two 6×his-tag coding sequences at both termini for 
one-step purification of expressed proteins, to construct recombinant expression plasmids of 
pET28a-ctb-cry j1 epi and pET28a-ctb-cry j2 epi. The structure and the cloning/expression 
region of pET28a are shown in Figure 2.2. Then, E. coli BL21 (DE3) competent cells were 
transformed with the expression plasmids, and positive colonies selected from LB/kanamycin 
plates were used in the expression and purification procedure. All the enzymatic digestion 
products were purified from the agarose gel using Gel Extraction Kit (Qiagen). 
DNA sequences of ctb-cry j1 epi and ctb-cry j2 epi in recombinant cloning plasmids and the 
orientations of the inserts in recombinant expression plasmids were analyzed using Thermo 
Sequenase Cy5.5 Dye Terminator Cycle Sequencing Kit (Amersham pharmacia). 
 
2.2.5 Construction of recombinant plasmids for B. subtilis 
 
2.2.5.1 Recombinant plasmid used for the insertion of the antigen gene in the genome of B. 
subtilis 
 
The structure of pHASH120 is shown in Figure 2.3. Upstream of RBS, SmaI is positioned for 
the cloning of optional promoters using the T-extension cloning method, and PS10 was used as 
the promoter in the study because it was proved one of the strongest promoters in B. subtilis. An 
interested gene amplified by PCR can be cloned in the T-extended EcoRV ends. The 
ampicillin-resistant and the part of tetracycline-resistant (∆tet) genes are derived from pBR322 
vector, the sequence between them can be integrated in the genome of B. subtilis BEST2131 by 
homologous recombination. 
T vector was prepared according to the method described by Ohashi et al [27]. Two µg 
pHASH120 was digested completely with 30U of EcoRV (Takara) at 37℃ for 6h and treated 
with phenol/chloroform extraction. After precipitation with ethanol, DNA was dissolved in 10µl 
of TE buffer. An aliquot of 5µl of the digested plasmid solution was treated with Ex Taq DNA 
polymerase (Takara) at a ratio of 2.5U/µg plasmid in 50µl buffer solution (1×Ex Taq buffer 
supplemented with 2mM dTTP) at 72℃ for 2h. After phenol/chloroform extraction twice and 
isopropanol precipitation, the T-vector was prepared by dissolving in 10µl of TE buffer and 
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stored at -80℃ until use.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Schematic structure of pHASH120 vector and the insertion site of the antigen gene 
Antibiotic-resistance genes indicated are: Amp, ampicillin; Cm, chloramphenicol; ∆Tc, part of 
tetracycline-resistant gene; Bs, blasticidin S 
(Ohashi Y, et al [27]. Far different levels of gene expression provided by an oriented cloning system in 
Bacillus subtilis and Escherichia coli. FEMS Micro Lett. 2003;221:125-130.) 
 
The gene of ctb-cry j1 epi was amplified by primers of CTB-FW (5’atgacacctcaaaatattac3’, 
the bolded sequence is the start codon) and Cry j1-RV (5’ttacgggccgaactggttga3’, the bolded 
sequence is the stop codon) from plasmid pUC18-ctb-cry j1 epi using Ex Taq DNA polymerase. 
PCR reaction conditions were as follows: 94℃, 5min preheating, followed by 35 cycles of 
denaturing (94℃, 15sec), annealing (55℃, 15sec) and elongation (72℃, 30sec), and an 
additional 7min reaction at 72℃ to add a dA nucleotide on both ends of the PCR product for 
the ligation with the T vector. The reaction of 100ng of the T-vector with 10-fold molar excess 
of purified PCR product was carried out at 16℃ for at least 6h using DNA Ligation Kit Ver.1 
(Takara) according to the method described in the manual.  
∆Tc Cm
Promoter (PS10)          ORF (ctb-cryj1 epi) 
Bs 
pHASH120 
5386bp Amp 
CCCT   AGGG 
GGGA   TCCC 
GATT   AATC 
CTAA   TTAG 
CCCGGG AAA GGA GG aaattGATATC 
SmaI       RBS         EcoRV 
SalI
XbaI 
BgllI 
PstI 
BgllI 
XbaI 
EcoRI
XbaI 
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The prepared recombinant plasmid named pHASH120-ctb-cry j1 epi was amplified in E. coli 
DH5α. Because of the possibility of two different orientations of ctb-cry j1 epi in the T-extended 
EcoRV ends of pHASH120, primers of EcoRI-SmaI-RBS-FW (5’ccggaattccccgggaaaggaggaaatt 
ga3’) and Cry j1-RV were used to search for the recombinant plasmid with the desired 
orientation of the antigen gene. Because EcoRI-SmaI-RBS-FW primer has corresponding 
sequence of RBS, but not that of ctb, the insert with unwanted orientation can not be amplified.  
The obtained recombinant plasmid with the desired orientation of the antigen gene was used 
for the transformation of B. subtilis BEST2131 to insert the antigen gene in the genome of the 
bacterium. The obtained positive strain was named as BEST2131-ctb-cry j1 epi. The genomes 
were extracted using QIAamp DNA mini Kit (Qiagen). Primers of CTB-FW and Cry j1-RV 
were used to confirm the insertion of ctb-cry j1 epi in the genome.  
 
2.2.5.2 Multi-copy plasmid used for the recovery of the antigen gene from the genome of B. 
subtilis  
 
The structure of pGETS103 is shown in Figure 2.4. The vector of pGETS103 consists of 
pTB522, a θ-type replicating plasmid in B. subtilis and the full length of E. coli plasmid 
pBR322, and can shuttle between E. coli and B. subtilis. It has two antibiotic resistance genes 
from pBR322 (ampicillin resistance and tetracycline resistance, which are only functional in E. 
coli), and one from pTB522 (tetracycline resistance, which is only functional in B. subtilis). 
Between pBR322-derived antibiotic resistance genes, there is a Hind III site, which was used for 
the linearization of the vector.  
The vector of pGETS103 was linearized prior to transformation. The linearized pGETS103 is 
unable to self-circularize, and circular pGETS103 can be established only after recovering the 
antigen gene from the genome by the homologous recombination mechanism. Linearized 
pGETS103 was prepared by digesting 1µg of pGETS103 with 10U of Hind III at 37℃ for 2h, 
followed by phenol/chloroform extraction and ethanol precipitation. The linearized pGETS103 
was used to transform B. subtilis BEST2131-ctb-cry j1 epi to recover the antigen gene from the 
genome by homologous recombination.  
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Figure 2.4 Schematic structure of pGETS103 vector 
Antibiotic-resistance genes indicated are: Amp, ampicillin; Tc, tetracycline-resistant gene, only 
functional in E. coli; TcB, tetracycline-resistant gene, only functional in B. subtilis. 
(Tsuge K and Itaya M [28]. Recombinational transfer of 100-kilobase genomic DNA to plasmid in 
Bacillus subtilis 168. J Bacteriol. 2001;183:5453-5458.) 
 
The vector of pGETS103 containing the antigen gene was recovered from the positive 
transformant. Primers of CTB-FW and Cry j1-RV were used to confirm the recovery of ctb-cry 
j1 epi in the plasmid. The recovered recombinant plasmid of pGETS103-ctb-cry j1 epi was 
amplifed in E. coli DH5α (20 copy number in E. coli compared with 9 in B. subtilis), and used 
for the transformation of B. subtilis 168 trpC2, which has no pBR322 sequences in the genome. 
The expression of CTB-Cry j1 epi was performed to test whether the expression of antigen gene 
was functional or not. 
 
2.2.6 Transformation method 
 
2.2.6.1 Transformation of E. coli 
 
Solution after plasmid ligation (2µl) or plasmid (10ng) was incubated with competent E. coli 
cells (20µl) for 5min on ice, followed by heat shock with 42℃ for 30sec. After 2min on ice, 
Amp    Tc
pTB522 
repA 
 TcB
Hind III 
pGETS103 
(14.5kbp) 
pBR322
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90µl SOC was added. Competent cells were grown at 37℃ under shaking for 1h and then 
applied on LB plate supplemented with an appropriate antibiotic, followed by incubation at 37
℃ overnight. 
Positive colonies transformed by recombinant plasmids of pUC18 or pET28a were selected 
on LB plates supplemented with ampicillin or kanamycin, respectively. Positive transformants 
transformed by pHASH120-ctb-cry j1 epi or pGETS103-ctb-cry j1 epi were selected on LB 
plate containing chloramphenicol or ampicillin.  
 
2.2.6.2 Transformation of B. subtilis 
 
2.2.6.2.1 Transformation of B. subtilis BEST2131 with the recombinant vector of 
pHASH120-ctb-cry j1 epi or linearized pGETS103 
 
Solutions used for the transformation are listed in Table 2.4 (I) and (II).  
A single colony of B. subtilis strain (BEST2131 or BEST2131-ctb-cry j1 epi) was inoculated 
in 1ml LB medium and grown under shaking at 37℃ for about 24h. The 24h-culture (50µl) and 
casamino acid (2%, 50µl) were added in TF-I (1ml), and the TF-I culture was continued to grow 
for another 4h under shaking at 37℃. Then, 0.4ml of the TF-I culture was added in 3.6ml of 
TF-II and grown for 1h at the same condition. After the centrifugation at 4000rpm for 15min (4
℃), 175µl of TF-II and 75µl of glycerol (50%) were added to suspend the cell pellet to prepare 
competent cells. Competent cells were stored at -80℃ until use.  
Competent cells (6.25µl), MgSO4・7H2O (2%, 1.25µl) and MgCl2 (1M, 1.25µl) were added 
in TF-D (50µl). Five µl of vector (pHASH120-ctb-cry j1 epi vector was used to transform B. 
subtilis BEST2131; and the linearized pGETS103 vector was used to transform B. subtilis 
BEST2131-ctb-cry j1 epi) was added and mixed well. The incubation was performed at 37℃ 
for 1h without shaking, followed by the addition of 200µl of LB medium and another 1h 
incubation at 37℃ under shaking.  
Transformants (BEST2131 transformed by pHASH120-ctb-cry j1 epi vector) were selected 
on LB plate supplemented with tetracycline, blasticidin S or chloramphenicol by incubation at 
37 ℃ overnight. Colonies which were only alive on LB plate supplemented with 
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chloramphenicol, were chosen as positive transformants. Transformants (BEST2131-ctb-cry j1 
epi transformed by the linearized pGETS103 vector) were selected on LB/plate supplemented 
with tetracycline or chloramphenicol. Colonies grown on both plates were chosen as positive 
transformants.  
 
Table 2.4 (I) Solutions used for the transformation of B. subtilis 
Component  10×Spizizen Medium A Medium B 
K2HPO4 140g 14g  
KH2PO4 60g 6g  
(NH4)2SO4 20g  2g 
Tri-sodium citrate dihydrate (C6H5O7Na3・2H2O) 10g  1g 
H2O to 1000ml to 50ml to 50ml 
 
Table 2.4 (II) Solutions used for the transformation of B. subtilis 
Component  TF-1 (ml) TF-II (ml) TF-D (ml) 
10×Spizizen soluton 100 100  
Medium A   0.625 
Medium B   6.25 
50% glucose 10 10 1.25 
2% MgSO4・7H2O 10 10  
2% casamino acid 10 5  
5 mg/ml tryptophan 10 1 1.25 
5 mg/ml arginine 10 1 1.25 
5 mg/ml leucine 10 1  
5 mg/ml histidine   1.25 
5 mg/ml threonine 10 1  
H2O to 1000 to 1000 to 100 
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2.2.6.2.2 Transformation of B. subtilis 168 trpC2 with the recombinant vector of 
pGETS103-ctb-cry j1 epi  
 
We found that the transformation method described above was not workable for the 
transformation of B. subtilis 168 trpC2 with the recombinant vector of pGETS103-ctb-cry j1 epi. 
This was probably due to the low concentration of vector resulting from its low copy number. 
We adopted the electroporation method [29] with some modifications and obtained positive 
transformants. 
B. subtilis 168 trpC2 were firstly grown in 2ml of LB medium with vigorous shaking at 37℃
overnight. A 200ml LB medium was inoculated with the overnight culture and incubated at 37
℃ under shaking until OD600 reached 1.5-2.0. Cells were harvested by centrifugation at 
3,000×g for 10min and washed three times (200ml/each time) in sterile cold ultrapure water 
and finally resuspened in 2ml of pre-chilled 30% polyethyleneglycol (PEG) 6000. The cells 
were then dispensed into 100µl aliquots, rapidly frozen in dry ice/ethanol and stored at -80℃。   
Electroporation was performed using the BTX electroporation system (Genetronisc). Cells 
(100µl) to be transformed were first thawed on ice, and 10µl of vector that had been dialyzed 
against deionized water was added, gently mixed and transferred to a pre-chilled 2mm gap 
electroporation cuvette. The cells were then immediately pulsed (2.5V, about 8msec of time 
constant at the resistance of 186Ω), diluted in 2ml of SOC medium and incubated at 37℃ with 
gently shaking (about 160rpm) for 1.5h. Chloramphenicol (0.2µg/ml) was added to the 
transformed cells in SOC after 1h incubation to induce resistance. Then 1ml of culture were 
centrifuged, and concentrated to 0.1ml, followed by being plated on LB plate.  
Transformants were selected on LB plate supplemented with tetracycline or chloramphenicol 
by incubation at 37℃ overnight. Colonies growing on both plates were selected as positive 
transformants. 
 
2.2.7 Extraction of plasmids  
 
Recombinant plasmids of pUC18 and pET28a from E. col JM109 were extracted using Spin 
Miniprep Kit (Qiagen).  
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Recombinant plasmids of pHASH120-ctb-cry j1 epi and pGETS103-ctb-cry j1 epi have very 
low copy number due to the pBR322-derived origin and/or the large size. In order to obtain 
satifactory concentrations, 50-400ml of LB culture was used for the growth of bacteria and the 
volume of the extracted plasmid in the elution buffer (EB buffer: 10mM Tris-HCl, pH 8.5) was 
50-100µl.  
In the extraction of pGETS103-ctb-cry j1 epi from E. coli DH5α using Spin Miniprep Kit, the 
elution solution was preheated to 70℃  prior to the elution. In the extraction of 
pGETS103-ctb-cry j1 epi from B. subtilis, Hispeed Plasmid Midi Kit (Qiagen) was used with 
some modifications on the method: cells were pelleted from 400ml of LB culture (OD600:  
0.8-1.2) by centrifugation at 3,000×g for 15min at 4℃ and resuspended in 16ml of Buffer P1 
containing 5mg/ml of lysozyme (from egg white, Wako); after incubation at 37℃ for 30min, 
16ml of Buffer P2 were added and mixed gently but thoroughly, then incubated at room 
temperature for 5min; pre-chilled Buffer P3 was added and mixed well, then incubated on ice 
for 15min followed by centrifugation at ≧ 20,000×g for 30min at 4℃; centrifuged again for 
15min; the supernatant was applied to QIAGEN-tip equilibrated with 4ml of Buffer QBT; 
QIAGEN-tip was washed twice with Buffer QC (10ml/each time); plasmid was eluted with 5ml 
of Buffer QF; plasmid was precipitated by adding 3.5ml of isopropanol at room temperature and 
centrifuging at ≧ 15,000×g for 30min at 4℃ , followed by washing with 2ml of 
room-temperature 70% ethanol and centrifuging at ≧ 15,000×g for 10min at 4℃; finally, the 
pellet was air-dried and redissolved in 100µl of the elution buffer.  
The extracted plasmid of pGETS103-ctb-cry j1 epi was dialysed for 1h on the semipermeable 
membrane (Spectra/Por membrane, MWCO 6-8000) against deionized water under stirring, and 
subsequently concentrated to the original volume by centrifugal filter devices (Microcon YM-10, 
Millipore) before the electroporation. 
 
2.2.8 Expression of antigen peptides 
 
2.2.8.1 Expression and purification of antigen peptides in E. coli 
 
A single positive colony of E. coli BL21 (DE3) transformed by pET28a-ctb-cry j1 epi or 
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pET28a-ctb-cry j2 epi was grown in 2ml of LB/kanamycin medium under shaking at 37℃ for 
about 6h. Culture was then induced with IPTG (Takara) at a final concentration of 1mM and 
grown overnight at 27, 32 and 37℃, respectively. Cells were pelleted by centrifugation and 
resuspended in 0.5ml of 20mM Tris-HCl (pH 8.0). After SDS-PAGE analysis, it was found that 
in both cultures expressing CTB-Cry j1 epi and CTB-Cry j2 epi, larger quantities of protein 
production were achieved at the induction temperature of 27℃.  
LB/kanamycin medium (50ml) was inoculated with 2ml of 5h culture of E. coli BL21 (DE3) 
transformants and grown under shaking at 37℃ for about 8h. The culture was induced with 
IPTG, and continued to grow overnight at 27℃ . The purification was performed using 
QIAexpress Type IV Kit (Qiagen) under denaturing conditions. Bacteria (0.5g wet weight) were 
harvested by centrifugation and resuspended in 2.5ml of the lysis buffer. After lysis under 
stirring for 60 min at room temperature, the lysate of bacteria was centrifuged, and the obtained 
supernatant was incubated with 0.6 ml of 50% Ni-NTA resin under shaking for 60 min at room 
temperature. Then the lysate-resin mixture was applied into a column. The flow-through was 
collected and the column was washed twice with the wash buffer (2.5ml/time). The recombinant 
protein was eluted with the elution buffer I (four times, 0.3 ml/time) followed by the elution 
buffer II (four times, 0.3ml/time). Fractions from the same buffer were pooled and applied to 
SDS-PAGE for analyis. Fractions of the elution buffer I and the elution buffer II were dialyzed 
against the dialysis solutions I-IV for 1.5h at room temperature respectively, and then against 
the dialysis solution V at 4℃ overnight. Buffers used are listed in Table 2.5.  
Protein yield was measured with BCA Protein Assay Reagent Kit (Pierce) using bovine serum 
albumin (BSA) as the standard. 
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Table 2.5 Buffers used for the purification of antigen peptides 
Buffer  Composition pH 
Lysis buffer 100 mM NaH2PO4, 10 mM Tris and 6 M GuHCl  8.0 
Wash buffer 100 mM NaH2PO4, 10 mM Tris and 8 M urea 6.3 
Elution buffer I 100 mM NaH2PO4, 10 mM Tris and 8 M urea 5.9 
Elution buffer II 100 mM NaH2PO4, 10 mM Tris and 8 M urea  4.5 
Dialysis solution I Tris-EDTA buffer, 8 M urea 8.0 
Dialysis solution II Tris-EDTA buffer, 4 M urea 8.0 
Dialysis solution III Tris-EDTA buffer, 2 M urea 8.0 
Dialysis solution IV Tris-EDTA buffer, 1 M urea 8.0 
Dialysis solution V Tris-EDTA buffer, 0M urea 8.0 
 
2.2.8.2 Expression and extraction of the antigen peptide in B. subtilis 
 
A single positive colony of B. subtilis 20038 (B. subtilis BEST2131 transformed by 
pHASH120, negative control), B. subtilis BEST2131 transformed by pHASH120-ctb-cry j1 epi, 
B. subtilis 168 trpC2 (negative control) or B. subtilis 168 trpC2 transformed by 
pGETS103-ctb-cry j1 epi was grown in 5ml of LB medium supplemented with chloramphenicol 
under shaking at 37℃ overnight. Bacteria were pelleted by centrifugation. The extraction of 
proteins was performed by adding 50µl of 2×SDS-PAGE sample buffer and heating for 5min at 
90℃. The suspension was centrifuged and 15µl of supernatant were applied on SDS-PAGE, 
followed by western blotting to detect the expression of the antigen peptide.   
 
2.2.9 SDS-PAGE 
 
Protein samples mixed with 2×SDS-PAGE sample buffer were heated for 5min at 90℃ and 
loaded on SDS-PAGE for separation. Running conditions were as follows: 100V for 30min 
followed by 200V for 40min. Proteins were visualized by the staining solution of Coomassie 
brilliant blue R-250.  
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2.2.10 Western blotting   
 
To test antigenicities of expressed antigen peptides, western blotting was performed. Proteins 
isolated on SDS-PAGE were transferred onto the PVDF transfer membrane (Amersham) by the 
semidry method. After blocked with 1% skim milk in phosphate buffered saline (PBS) for 1h at 
room temperature or overnight at 4℃, the membrane was incubated with the primary antibody 
for 1h at room temperature. Rabbit anti-cholera toxin antibody (1:5000 dilution, Sigma) was 
used as the primary antibody for both CTB-Cry j1 epi and CTB-Cry j2 epi, and rabbit anti-Cry 
j1 antibody (1:400 dilution, Hayashibara) and rabbit anti-Cry j2 antibody (1:400 dilution, LSL) 
were used as primary antibodies for CTB-Cry j1 epi and CTB-Cry j2 epi, respectively. Then the 
incubation with the secondary antibody (horseradish peroxidase-conjugated donkey anti-rabbit 
IgG, 1:25000 dilution, Amersham) was performed for 1h at room temperature. After the 
blocking and each incubation step, the membrane should be washed fully with PBS containing 
0.5% Tween-20, ensuring to eliminate nonspecific absorption of milk or antibody completely. 
Signal was detected by ECL detection reagents (Amersham). Commercial CTB (Sigma), 
commercial Cry j1 antigen (Hayashibara) or commercial Cry j2 antigen (Hayashibara) were 
used as the positive controls. 
 
2.3 Results and discussion 
 
2.3.1 Selection of major T cell epitopes from Cry j1 and Cry j2 
 
Major T cell epitopes from Cry j1 and Cry j2 were selected based on the features of epitopes 
summarized in Table 2.6, which contains available epitopes from Cry j1 and Cry j2 for the 
design of immunotherapeutics, MHC class II types of human (HLA) presenting the epitopes, the 
reactivity of Cry j1 or Cry j2-specific T cell line against the epitopes as well as the finally 
selected epitopes in the literature [14]. In the literature, the epitopes containing the cysteine 
residue at the end were modified by removing them and those containing the cysteine residue in 
the middle position were eliminated regardless of the strength of the epitopes, based on the 
reason that influences of the cysteine residue on the release of epitopes from an artificial 
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polypeptide remain unknown. In addition, epitopes with the reactive ratio of 50% and 
undetermined HLA type were also eliminated.  
 
Table 2.6 Analysis for the epitope selection in the literature [14] 
Allergen Available epitope HLA type 
Positive response 
(Strong positive response)% 
Selected peptide 
16-30 DQ6 61 (45)  
66-80 Not determined 50 (11)  
81-95 Not determined 61 (17)  
91-105 DQ6 50 (11)  
106-120 DR51 72 (28) 108-120 
111-125 Not determined 55 (28)  
212-224 DP5 72 (33) 211-225 
301-315 Not determined 56 (11)  
Cry j1 
316-330 Not determined 50 (22)  
77-89 DR51 61 (39) 75-89 
90-104 DP5 50 (28)  
150-164 Not determined 56 (0)  
195-209 DR53 67 (28) 191-209 
245-259 DR15 50 (17)  
345-359 DP5 50 (22) 
355-369 DQ6 67 (28) 
Cry j2 
360-374 Not determined 61 (22) 
353-364 
 
However, we have some different ideas in the selection of T cell epitopes from Cry j1 and 
Cry j2. In the study, the effect of the cysteine residue was not considered. All the epitopes with 
reactivity higher than 50% as well as the strong reactivity higher than 15% were selected. 
Because Cry j2-96-107 possesses very strong reactivity based on another literature [9], it was 
chosen in stead of Cry j2-90-104. Because Cry j2-245-259 is presented by DR15 that was the 
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sole type among the selected HLA class II molecules, it was used as an epitope in order to 
achieve sufficient efficacy in a large population of allergic patients in spite of the reactivity of 
50%. Cry j2-345-374 is a very important region for the design of the antigen peptide, therefore 
it was also selected in the study. Selected peptides and epitopes included are summarized in 
Table 2.7. Because effects of the arrangement of the individual epitope in the linked peptide on 
the antigenicity have not been well defined, they will be fused to CTB according to the original 
amino acid sequence order in the allergen protein in this study. 
 
Table 2.7 Selected peptides and epitopes included from Cry j1 and Cry j2 in the study  
Cry j1 Cry j2 
Peptide Epitopes included Peptide Epitopes included 
Cry j1-16-30 1 Cry j2-77-89 1 
Cry j1-81-95 1 Cry j2-96-107 1 
Cry j1-106-125 2 Cry j2-191-209 1 
Cry j1-212-224 1 Cry j2-245-259 1 
  Cry j2-345-374 3 
 
2.3.2 Construction of fusion genes 
 
The forward primer used for the construction of fusion genes, was designed according to the 
beginning coding sequence of CTB gene. The reverse primer consists of a complementary part 
with the template and an overhang of epitope gene. PCR was employed to add the epitope gene 
to the template stepwise, resulting in the final product with five Cry j1 epitope genes or seven 
Cry j2 epitope genes linked to CTB gene, respectively.  
Sizes of resultant PCR products visualized on the agarose gel (Figure 2.5) are in good 
agreement with the calculated ones shown in Table 2.8, suggesting that epitope genes from Cry 
j1 or Cry j2 were successfully linked to CTB gene by this method. Moreover, results of 
sequencing analysis showed that sequences were identical to the designed ones and had correct 
orientations in expression plasmids. Nucleotide sequences and amino acid sequences of 
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CTB-Cry j1 epi and CTB-Cry j2 epi are shown in Figure 2.6. The final products were cloned 
into the cloning plasmid of pUC18, and then the expression plasmid of pET28a.  
                           
         
                     (a)                             (b) 
Figure 2.5 Electrophoretic analysis of products acquired from stepwise PCR 
(a) PCR products in the linkage of CTB-Cry j1 epi gene. Lane 1, 200 bp marker; Lane 2, CTB gene; 
Lane 3, CTB-P1 gene; Lane 4, CTB-P1-P2 gene; Lane 5, CTB-P1-P2-P3 gene; Lane 6, 
CTB-P1-P2-P3-P4 gene; Lane 7, CTB-P1-P2-P3-P4-P5 gene (final product). (b) PCR products in 
the linkage of CTB-Cry j2 epi gene. Lane 1, 200bp marker; Lane 2, CTB gene; Lane 3, CTB-P’1 
gene; Lane 4, CTB-P’1-P’2 gene; Lane 5, CTB-P’1-P’2-P’3 gene; Lane 6, CTB-P’1-P’2-P’3-P’4 
gene; Lane 7, CTB-P’1-P’2-P’3-P’4-P’5 gene; Lane 8, CTB-P’1-P’2-P’3-P’4-P’5-P’6 gene; Lane 9, 
CTB-P’1-P’2-P’3-P’4-P’5-P’6-P’7 gene (final product). 
 
Table 2.8 Calculated sizes of stepwise PCR products 
Linkage of Cry j1 epitope genes to CTB gene Linkage of Cry j2 epitope genes to CTB gene 
Reaction order Primer name Product size (bp) Reaction order Primer name Product size (bp)
1 P1 354 1 P’1 348 
2 P2 399 2 P’ 2 384 
3 P3 429 3 P’3 414 
4 P4 459 4 P’4 441 
5 P5 498 5 P’5 486 
   6 P’6 531 
   7 P’7 576 
 
1  2  3  4  5  6  7  1  2  3  4  5  6  7  8   9 
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(a)  
DNA sequence of CTB-Cry j1 epi  
ACACCTCAAAATATTACTGATTTGTGTGCAGAATACCACAACACACAAATACATACGCTAAATGATAAGAT
ATTTTCGTATACAGAATCTCTAGCTGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAACTT
TTCAAGTAGAAGTACCAGGTAGTCAACATATAGATTCACAAAAAAAAGCGATTGAAAGGATGAAGGATA
CCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCGAAAAGTTATGTGTATGGAATAATAAAACGCCTCAT
GCGATTGCCGCAATTAGTATGGCAAAT−CAGAACCGTATGAAACTGGCGGATTGCGCGGTGGGCTTCGGC
AGC−AAAATGCCGATGTATATTGCGGGCTATAAAACGTTCGATGGCCGT−CCGTGCGTGTTCATTAAACGT
GTGAGCAACGTGATTATTCATGGCCTGCATCTGTATGGC−AGCATGAAAGTGACGGTGGCGTTCAACCAG
TTCGGCCCG  
 
Amino acid sequence of CTB-Cry j1 epi 
TPQNITDLCAEYHNTQIHTLNDKIFSYTESLAGKREMAIITFKNGATFQVEVPGSQHIDSQKKAIERMKDTLRI
AYLTEAKVEKLCVWNNKTPHAIAAISMAN−QNRMKLADCAVGFGS−KMPMYIAGYKTFDGR−PCVFIKRVS
NVIIHGLHLYG−SMKVTVAFNQFGP 
 
(b) 
DNA sequence of CTB-Cry j2 epi gene 
ACACCTCAAAATATTACTGATTTGTGTGCAGAATACCACAACACACAAATACATACGCTAAATGATAAGAT
ATTTTCGTATACAGAATCTCTAGCTGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAACTT
TTCAAGTAGAAGTACCAGGTAGTCAACATATAGATTCACAAAAAAAAGCGATTGAAAGGATGAAGGATA
CCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCGAAAAGTTATGTGTATGGAATAATAAAACGCCTCAT
GCGATTGCCGCAATTAGTATGGCAAAT−GGCATTATTGCGGCGTATCAGAACCCGGCGAGCTGGAAA−CA
GTTCGCGAAACTGACGGGCTTCACGCTGATGGGC−ATTGATATTTTCGCGAGCAAAAACTTCCATCTGCA
GAAAAACACGATTGGCACGGGC−AGCCGTGCGGAAGTGAGCTATGTGCATGTGAACGGCGCGAAATTC−
TGCAAAGATATTAAACTGAGCGATATTAGCCTGAAACTGACGAGCGGCAAAATTGCGAGCTGCCTGAAC
GATAACGCGAACGGCTATTTC 
 
Amino acid sequence of CTB-Cry j2 epi 
TPQNITDLCAEYHNTQIHTLNDKIFSYTESLAGKREMAIITFKNGATFQVEVPGSQHIDSQKKAIERMKDTLRI
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AYLTEAKVEKLCVWNNKTPHAIAAISMAN−GIIAAYQNPASWK−QFAKLTGFTLMG−IDIFASKNFHLQKNTI
GTG−SRAEVSYVHVNGAKF−CKDIKLSDISLKLTSGKIASCLNDNANGYF 
 
Figure 2.6 Nucleotide sequences and amino acid sequences of fusion proteins 
(a) Sequences of DNA and amino acids of CTB-Cry j1 epi. The order of linkage is CTB−Cry 
j1-16-30−Cry j1-81-95−Cry j1-106-125−Cry j1-212-224. (b) Sequences of DNA and amino acids of 
CTB-Cry j2 epi. The order of linkage is CTB−Cry j2-77-89−Cry j2-96-107−Cry j2-191-209−Cry 
j2-245-259−Cry j2-345-374. 
 
2.3.3 Expression and antigenicities of antigen peptides expressed in E. coli 
 
2.3.3.1 Purification of antigen peptides  
 
High expression levels of recombinant antigen peptides in E. coli led to the formation of 
insoluble inclusion bodies, which can be solubilzed with strong denaturants such as 8M urea or 
6M guanidine hydrochloride. In the study, 6M guanidine hydrochloride, rather than 8M urea 
was proved an effective denaturant and applied in the purification of antigen peptides.  
 
                                                                  
 
 
 
 
 
(a)                                       (b) 
Figure 2.7 Purification of recombinant antigen peptides on the Ni-NTA resin affinity column 
(a) CTB-Cry j1 epi (b) CTB-Cry j2 epi. Lane 1, Molecular weight marker; Lane 2, Crude protein of 
CTB; Lane 3, Crude protein; Lane 4, lysate supernatant; Lane 5, Lysis debris; Lane 6, Flow-through; 
Lane 7, Washed fraction; Lane 8, Eluted fraction I; Lane 9, Eluted fraction II. Five µl protein 
samples were applied on SDS-PAGE. 
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A single band with high homogeneity was obtained from eluted fractions of the elution buffer 
I and II. Molecular mass of the antigen peptide visualized on SDS-PAGE (Figure 2.7) was in 
good agreement with the theoretical one: 23.7 kDa for CTB-Cry j1 epi or 26.3 kDa for 
CTB-Cry j2 epi.  
Protein quantity measurement showed antigen peptides were efficiently expressed in E. coli, 
giving about 11 and 18 mg/L culture of purified CTB-Cry j1 epi and CTB-Cry j2 epi, 
respectively.  
It was found that Cry j1 epi and Cry j2 epi could not be expressed without CTB fused to them, 
indicating that CTB also functions to stabilize short peptides expressed in microorganism-based 
systems (data not shown). 
 
2.3.3.2 Antigenicities of antigen peptides  
                                                                      
                     
(a)                 (b)              (c) 
Figure 2.8 Antigenicities of purified antigen peptides  
(a) The primary antibody used was anti-cholera toxin antibody. Lane 1, Commercial CTB; Lane 2, 
Purified CTB-Cry j1 epi; Lane 3, Purified CTB-Cry j2 epi. (b) The primary antibody used was 
anti-Cry j1 antibody. Lane 1, Commercial Cry j1 antigen; Lane 2, Purified CTB-Cry j1 epi. (c) The 
primary antibody used was anti-Cry j2 antibody. Lane 1, Commercial Cry j2 antigen; Lane 2, 
Purified CTB-Cry j2 epi.  
One µl of commercial CTB (0.25µg/µl, MW 11kDa), 1µl of commercial Cry j1 antigen (0.1µg/µl, 
MW 50kDa) or Cry j2 antigen (0.1µg/µl, MW 37kDa), and 5µl of purified antigen peptides of 
CTB-Cry j1 epi (0.26µg/µl, MW 24kDa) or CTB-Cry j2 epi (0.31µg/µl, 27kDa) were analyzed. 
 
1    2    3 1   2 1   2  
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To assess antigenicities of antigen peptides, western blotting was performed (Figure 2.8). The 
purified recombinant antigen peptides were proved antigenic against corresponding antibodies, 
i.e. CTB-Cry j1 epi was recognized by anti-cholera toxin and anti-Cry j1 antibodies; and 
CTB-Cry j2 epi was recognized by anti-cholera toxin and anti-Cry j2 antibodies.  
In addition, anti-cholera toxin antibody did not recognize Cry j1 and Cry j2 antigens and 
anti-Cry j1 and anti-Cry j2 antibodies did not recognize CTB, and also anti-Cry j1 antibody did 
not recognize Cry j2 and vice versa (figure not shown). The result suggested no occurrence of 
cross-reactivity, consequently eliminating possibilities of false positive results.  
 
2.3.4 Insertion of the antigen gene in the genome of B. subtilis BEST2131 
 
The ctb-cry j1 epi gene was cloned in the T-extended EcoRV ends of pHASH120. pHASH120 
possesses two pBR322-derived antibiotic genes, the ampicillin-resistant gene and part of 
tetracycline-resistant (∆tet) gene that is not functional. pBR322-derived antibiotic genes are 
inert in B. subtilis. The vector also has a chloramphenicol-resistant gene and a blasticidin 
S-resistant gene, which are functional both in E. coli and in B. subtilis. pHASH120 is unable to 
self-replicate in B. subtilis.  
B. subtilis BEST2131 has pBR322 sequences and an insertion of tetracycline-resistant gene 
between them in the leuB gene (leuB::pBRTc) of B. subtilis 168 trpC2 genome. The 
tetracycline-resistant gene is only functional in B. subtilis.  
The pBR322-derived sequences in the recombinant plasmid pHASH120 in the transformed 
BEST2131 can combine with the homologous sequences present in the BEST2131 genome, 
therefore hereafter the exchange of sequences in the plasmid and in the genome will happen 
naturally. The process is called homologous recombination. As a result, the genome obtained the 
ctb-cry j1 epi gene together with the promoter and RBS, which function to express the antigen 
peptide in B. subtilis genome. At the same time, BEST2131 with ctb-cry j1 epi inserted in the 
genome becomes sensitive to tetracycline and also blasticidin S, but acquires the ability against 
chloramphenicol. Figure 2.9 shows the schematic insertion process of the antigen gene in the 
genome of BEST2131 and the change in the antibiotic resistance before and after the insertion 
of the antigen gene.  
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Figure 2.9 Schematic integration procedure of the antigen gene in the B. subtilis genome by 
homologous recombination via pBR322 sequences 
Antibiotic-resistance genes indicated are: Amp, ampicillin; Cm, chloramphenicol; ∆Tc, part of 
tetracycline-resistant gene; Bs, blasticidin S; TcB, tetracycline-resistant gene only functional in B. 
subtilis. R and S refer to “resistant” and “sensitive”, respectively.   
 
2.3.5 Recovery of the antigen gene from the genome to a multi-copy plasmid  
 
In order to test whether the antigen gene is functional or not, the vector of pGETS103 was 
used to revover the antigen gene from the genome.  
The vector of pGETS103 is a multi-copy shuttle vector between E. coli and B. subtilis, the 
copy number was estimated to be 9 for B. subtilis and 20 for E. coli. The vector of pGETS103 
consists of pTB522, a θ-type replicating plasmid in B. subtilis from a thermophilic Bacillus 
strain and the full length of E. coli plasmid pBR322. Two antibiotic resistance genes are from 
pBR322 (ampicillin resistance and tetracycline resistance, which are only functional in E. coli), 
and one from pTB522 (tetracycline resistance, which is only functional in B. subtilis).  
The vector of pGETS103 was linearized at the unique Hind III site prior to transformating B. 
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subtiils BEST2131-ctb-cry j1 epi. The linearized pGETS103 is unable to self-circularize, thus 
loses the ability of self-replication in B. subtilis. Circular pGETS103 can be established only 
after recovering the antigen gene from the genome of BEST2131-ctb-cry j1 epi by the 
homologous recombination. The circular plasmid then renders B. subtilis resistant to 
tetracycline. The process of recombinational transfer comprises four discrete steps: uptake of 
the linearized pGETS103, formation of homologous pairs, occurrence of recombination, and 
amplification of the plasmid [28]. Figure 2.10 shows the schematic process of extraction of the 
antigen gene from the genome to the plasmid. 
It should be noted that the insertion of the antigen gene in the plasmid interferes with the 
downstream expression of pBR322-derived tetracycline resistant gene, resulting in the 
destruction of tetracycline-resistant activity in E. coli. But pTB522-derived tetracycline resistant 
gene was also functional in B. subtilis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Schematic transfer procedure of the integrated antigen gene at the B. subtilis 
genomic pBR locus to a multi-copy plasmid by homologous recombination 
Antibiotic-resistance genes indicated are: Amp, ampicillin; TcE, tetracycline-resistant gene only 
functional in E. coli; TcB, tetracycline-resistant gene only functional in B. subtilis; Cm, 
chloramphenicol; Bs, blasticidin S.  R and S refer to “resistant” and “sensitive”, respectively.   
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2.3.6 Confirmation of insertion of ctb-cry j1 epi gene in plasmids and the genome  
 
PCR products amplified from pHASH120-ctb-cry j1 epi, the BEST2131-ctb-cry j1 epi 
genome and pGETS103-ctb-cry j1 epi are shown in Figure 2.11.  
Results suggested that we could obtain pHASH120-ctb-cry j1 epi in which the antigen gene 
was inserted in the desired orientation. This also guaranteed the correct insertion of the antigen 
gene in the genome. The insertion of the antigen gene in the genome and the recovery of the 
antigen gene from the genome to pGETS103 were also confirmed.  
 
      
(a)                    (b)                    (c) 
Figure 2.11 Electrophoretic analysis of PCR products to confirm the insertion of ctb-cry j1 epi   
(a) Confirmation of ctb-cry j1 epi in pHASH120-ctb-cry j1 epi. Lane 1, 200 bp marker; Lane 2, PCR 
product (b) Confirmation of ctb-cry j1 epi in the BEST2131-ctb-cry j1 epi genome. Lane 1, 200 bp 
marker; Lane 2 and 3, PCR products from colony No.1 and No. 2 (c) Confirmation of ctb-cry j1 epi 
in pGETS103-ctb-cry j1 epi. Lane 1, 200 bp marker; Lane 2, PCR product. 
 
2.3.7 Expression of the antigen peptide in B. subtilis 
 
The expression of CTB-Cry j1 epi in B. subtilis was examined by western blotting. CTB-Cry 
j1 epi was successfully expressed in B. subtilis when the gene was inserted in the plasmid, but 
little expression was observed when the antigen gene was integrated in the genome of B. subtilis 
(Figure 2.12). To test whether the antigen gene in the genome is functional or not, the inserted 
ctb-cry j1 epi gene in the genome was recovered by a multi-copy plasmid pGETS103, and 
CTB-Cry j1 epi was expressed in B. subtilis 168 trpC2. Results (Figure 2.12) indicated that 
1   2  1   2   3 1   2   
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much quantity of CTB-Cry j1 epi was expressed in pGETS103. This indicated that the 
expression of the antigen gene was functional in the plasmid. 
It should be noted that CTB-Cry j1 epi expressed in E. coli has larger molecular weight than 
that expressed in B. subtilis, which is due to the introduction of additional amino acids from the 
recombinant plasmid of pET28a to CTB-Cry j1 epi. The band below the CTB-Cry j1 epi (from 
pGETS103) expressed in B. subtilis 168 trpC2 may be its degraded product.  
 
  
       (a)                                   (b) 
Figure 2.12 Expression of the ctb-cry j1 epi gene in B. subtilis (detected by western blotting) 
Experiments were performed according to the method described in Materials and methods 2.2.8.2. 
Briefly, 5ml of LB culture of B. subtilis was pelleted and 50µl of 2×SDS-PAGE sample buffer was 
added to extract proteins by heating for 5min at 90℃.   
(a) The primary antibody used was anti-cholera toxin antibody. Lane 1, Commercial CTB; Lane 2, E. 
coli expressiong CTB-Cry j1 epi from pET28a; Lane 3, B. subtilis BEST20038 (BEST2131 
transformed by pHASH120, negative control); Lane 4, B. subtils BEST2131-CTB-Cry j1 epi, colony 
No.1; Lane 5, B. subtils BEST2131-CTB-Cry j1 epi, colony No.2; Lane 6, B. subtilis 168 trpC2 
(negative control); Lane 7, B. subtilis 168 trpC2 expressing CTB-Cry j1 epi from pGETS103. (b) 
The primary antibody used was anti-Cry j1 antibody. Lane 1, Commercial Cry j1 antigen; Lane 2, E. 
coli expressiong CTB-Cry j1 epi from pET28a; Lane 3, B. subtilis 168 trpC2 expressing CTB-Cry j1 
epi from pGETS103.  
Two µl of commercial CTB (0.25µg/µl, MW 11kDa), 3µl of commercial Cry j1 antigen (0.1µg/µl, 
MW 50kDa), 7.5µl of E. coli suspension expressing CTB-Cry j1 epi (MW 24kDa) from pET28a and 
15µl of extraction from B. subtilis without or with CTB-Cry j1 epi (MW 19kDa) gene in the genome 
or in pGETS103 were analyzed. The arrow indicated the band of expressed CTB-Cry j1 epi.  
1   2            3  1     2     3    4     5     6    7 
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It was assumed that the undetectable expression of the antigen peptide from the gene in the 
genome might be due to: (1) single copy number of the antigen gene in the genome; (2) some 
unknown factors in the genome which affected the nomal expression of the inserted gene; (3) 
insufficient sensitivity and specificity of the methods to detect the antigen protein.  
Middile wall protein (MWP) promoters from Bacillus brevis 47 are stronger promoters for 
the transcription of mRNA, therefore the stronger expression of proteins [30]. However, even if 
MWP promoters were used as the promotor of the antigen gene, no detectable amount of the 
antigen peptide from the gene in the genome was observed (data not shown). Complex factors 
in the genome for the expression of the foreign protein should be investigated.  
 
2.4 Summary 
 
Up to five major T cell epitopes from Cry j1 and seven from Cry j2 were selected on the basis 
of references in the study. To utilize the ability of CTB as the adjuvant and carrier, two 
genetically engineered fusion peptides, CTB-Cry j1 epi and CTB-Cry j2 epi, were designed. 
Genes encoding epitopes from Cry j1 or Cry j2 were fused to CTB gene in tandem by PCR. 
Results of sequencing analysis showed that sequences were identical to the designed ones and 
had correct orientations in expression plasmids.  
Fusion genes were expressed firstly in E. coli. The expressed CTB-Cry j1 epi and CTB-Cry 
j2 epi were purified to a high homogeneity with Ni-NTA resin, giving about 11 and 18 mg/L 
culture of purified peptides, respectively. Results of antigenic reactivity by western blotting 
showed that recombinant CTB-Cry j1 epi or CTB-Cry j2 epi was recognized specifically by 
anti-cholera toxin as well as anti-Cry j1 (or anti-Cry j2) antibodies.  
Natto is an ideal food carrier for the treatment of Japanese cedar pollinosis, because it is 
easily made and full of nutrients, and most importantly, is the favorite food of Japanese people. 
B. subtilis (natto) used for the fermentation of natto, is a closely related strain to B. subtilis 168 
trpC2. The gene regulation of natto fermentation can function in B. subtilis 168 trpC2 if the 
relevant genes are appropriately transferred to corresponding loci of the genome by repeated 
transformation of B. subtilis 168 trpC2 with the genomic DNA from B. subtilis (natto). In the 
study, the ctb-cry j1 epi gene was inserted in the genome of B. subtilis BEST2131 (a strain with 
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pBR322 sequences in the leuB gene of 168 trpC2) by homologous recombination, which 
happened between two homologous DNA segments, i.e. pBR322-derived sequences, one in the 
BEST2131 genome and the other in the plasmid pHASH120 containing the antigen gene. The 
expression of CTB-Cry j1 epi from the gene in the genome of B. subtilis was not detected. To 
test whether the antigen gene is functional or not, the inserted ctb-cry j1 epi gene in the genome 
was recovered by a multi-copy plasmid pGETS103, and CTB-Cry j1 epi was expressed in B. 
subtilis 168 trpC2. Results indicated that much quantity of CTB-Cry j1 epi was expressed in 
pGETS103, suggesting the antigen gene is functional in plasmid. Complex factors in the 
genome for the expression of the foreign protein should be investigated.  
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Chapter 3 
 
Utilization of CTB as a transporter: 
Expression of pentameric CTB and an attempt to assemble holotoxin-like 
complex in a cell-free system 
 
 
3.1 Introduction 
 
The post-genomic era brings many challenges to the understanding of protein structure, 
function and interation. Due to fast growth, easy handling and low cost, E. coli has long been 
the primary prokaryotic host for heterologous protein expression [31, 32]. However, the 
expression and accumulation of a foreign protein in E. coli often cause aggregates of the protein 
to form insoluble inclusion bodies [33, 34]. Sometimes the protein in these inclusion bodies can 
be refolded in vitro to produce functional protein [35, 36], but this is not always possible, and 
renaturation can be expensive and time-consuming. Moreover, many proteins, for example, 
structurally complex oligomeric proteins and those containing multiple disulfide bonds, are not 
easily recovered to an active conformation following chemical denaturation [34]. The 
expression of heterologous proteins in other bacterial systems also often encounters the same 
problems as those in E. coli. All these restrict the application of bacteria-based systems in the 
expression of structurally complex oligomeric proteins.  
Since the advent of the first real cell-free protein expression system in the 1950s, the cell-free 
system has attracted considerable attention as an alternative protein synthesis method, especially 
with the appearance of highly productive, commercial kits, which are available for the 
convenient production of a broad variety of proteins. The cell-free system is an in vitro protein 
expression system. It contains all the necessary elements for the expression of proteins, such as 
ribosome, enzymes, translation factors, amino acids, tRNA, energy source supplied by ATP and 
GTP, buffers and salts such as Mg, and DNA or mRNA is used as the template. Two cell-free 
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protein expression systems are available: the prokaryotic system based on the E. coli lysate and 
the eukaryotic system based on the rabbit reticulocyte extract or the wheat germ embryo extract.  
Continuous exchange cell-free (CECF) technology was proposed firstly by Spirin et al [37]. 
The schematic working principle of CECF is shown in Figure 3.1. This technology provides 
continuous removal of by-products and a steady supply of substrates necessary to sustain the 
reaction, resulting in high levels of protein synthesis. This is realized by employing a 
semi-permeable membrane (10kDa cut-off) to create two compartments in the reaction vessel: a 
reaction compartment in which transcription/translation occurs and the protein product is 
retained; a feeding compartment into which inhibitory reaction by-products diffuse and from 
which reaction substrates and energy components are continuously supplied for sustained 
synthesis.  
 
 
Figure 3.1 Continuous exchange cell-free (CECF) technology 
(https://www.roche-applied-science.com/sis/proteinexpression/index.jsp) 
 
The cell-free system provides powerful tools to synthesize any desired protein, including 
native proteins, proteins toxic to living cells and artificially modified proteins [37]. Moreover, 
the cell-free system has the strong ability in expressing soluble, properly folded proteins [38]. 
Most attractively, in contrast to bacterial expression systems, the cell-free system offers 
considerable flexibility to investigate the interaction of proteins by coexpressing them.  
Fundamentals to the cell-free system are rational gene design, usage of linear or circular 
template with optional tag in N- or C- terminus for purification, and expression screening and 
scale up. The schematic experimental flowchart (take the E. coli cell-free system as an example) 
is shown in Figure 3.2. To use the system, the gene of interest must be positioned downstream 
 43
of a T7 promoter and between an optimized 5’- and 3’- UTR (untranslated region). The vector 
used for expression should include the following elements and structural features: target gene 
must be under control of T7 promoter that is located downstream from an RBS sequence; 
distance between T7 promoter and an initiating ATG triplet should not exceed 100 base pairs; 
distance between RBS sequence and the ATG should not be more than 5-8 base pairs; and T7 
terminator sequence must be present at the 3’ end of the gene. In theory, any vector with this 
elements and features can be used.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Combined or coupled in vitro transcription/translation in the cell-free system 
(Part of the figure quoted from RTS application manual for cell-free protein expression ) 
 
Generation of linear or circular template 
(addition of elements necessary for the expression of protein) 
 
Gene from cDNA or designed by software service 
Transcription of mRNA and expression of protein 
in a combined or coupled format 
 
Scale up of the expression 
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It was found that CTA interacted with CTB primarily through its A2 domain, which inserted 
into the center of the ring formed by CTB pentamer, and CTA1 was not required to maintain the 
stability of the noncovalent interactions between CTA2 and B pentamer [39]. The interactions 
between CTA2 and B pentamer that occur within the upper end of the pentamer pore are 
exclusively hydrophobic, while the interactions that occur in the lower regions of the pentamer 
core are largely hydrophilic [40]. It was also found that CTA would only associate with CTB 
that was in the process of assembling, i.e. the pathway of holotoxin assembly involved the 
association of CTA, not with the fully assembled CTB pentamer, but with CTB intermediate 
[41]. In addition, the disulfide bond formation (between the cysteine residues of Cys-9 and 
Cys-86 in CTB) is required to generate and stabilize correctly structured B monomers capable 
of forming pentamer [42].  
A new strategy for the delivery of vaccines and antigens is to genetically engineer the 
interested peptide or protein linked to the nontoxic CTA2 segment and coexpress CTB to create 
a holotoxin-like chimera for generating CT-based mucosal vaccines or antigens with reduced 
toxicity and high efficiency. However, to our knowledge, the recombinant CTB expressed in E. 
coli was in an insoluble form, which is the greatest obstacle for the assembly of holotoxin-like 
complex. The only in vitro assembly method involved denaturation and reactivation of 
CTA2-fusion protein and CTB, which was troublesome and actually difficult for the practical 
application [43].  
RTS 100 E. coli Disulfide Kit (50µl/reaction) developed by Roche is a CECF system based 
on E. coli lysate for the expression of disulfide bonded proteins from plasmid templates. The kit 
uses the redox buffer to maintain the system under oxidizing conditions, the disulfide isomerase 
for the formation and the rearrangement of disulfide bonds, and increased amounts of GroE 
chaperones to guarantee the production of soluble, properly folded proteins. The kit can provide 
the platform to assemble the holotoxin-like complex by coexpressing CTB and the fusion 
protein of interested peptide or protein with CTA2 simultaneously. However, before the 
assembly of the holotoxin-like complex is performed, the ability of CTB in the formation of 
pentamer has to be verified.  
Assembling cholera toxin-like complex by coexpressing CTB and the fusion protein of green 
fluorescence protein (GFP) linked to CTA2 in the cell-free system was attempted. GFP was 
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selected as a model protein because of no requirement of cofactors and substrates for 
fluorescence activity, allowing for direct, real-time detection. 
 
3.2 Material and methods 
 
3.2.1 Bacterial strains, plasmids and media 
 
E. coli strain JM109 (Takara) was used for the cloning of recombinant plasmid pET28a, and 
kanamycin (25µg/ml) was used as the selection antibiotic for the positive transformants. E. coli 
strain BL21 (DE3) (Novagen) was used for the expression of CTB. E. coli strain XL1 blue was 
used for the cloning of recombinant plasmid of pIVEX2.4d (Roche), and ampicillin (50µg/ml) 
was used as the selection antibiotic. pEGFP vector (Clontech), harboring the enhanced green 
fluorescent protein (EGFP) gene, was amplified in E. coli strain JM109 with the selection by 
ampicillin (100µg/ml). E. coli transformation method was according to Materials and methods 
2.2.6.1 of chapter 1. All the E. coli strains were grown at 37℃ in LB medium supplemented 
with the appropriate antibiotic. 
Kanamycin and ampicillin were purchased from Wako and Sigma, respectively.  
 
3.2.2 Construction of genes by PCR amplification 
 
Genes of ctb with different structures and gfp-cta2 fusion gene were constructed using the 
primers shown in Table 3.1. CT gene (PCR product from the genome of Vibrio cholerae strain 
569B, kindly provided by Prof. Takeshi Honda of Osaka University) was applied as templates 
for the construction of ctb and cta2 genes. In the case of the construction of ctb genes, primers of 
BamHI-CTB-FW and CTB-RV-Hind III-2 were used to introduce the BamHI site to 5’ and the 
Hind III site to 3’ of ctb gene, and after cloned in pET28a, the expressed CTB had an N-terminal 
His×6 tag followed by an extra segment of 22 amino acids which was introduced by the 
recombinant plasmid pET28a; primers of NcoI-CTB-FW and CTB-BamHI-RV were used to 
introduce NcoI and BamHI sites, the resultant CTB having the structure nearly the same with 
the natural one, was obtained after cloned in pET28a; forward primers of His×3-CTB-FW and 
 46
NcoI-His×6-CTB-FW, and the reverse primer of CTB-BamHI-RV were used to introduce a 
His×6 tag which was directly attached to N-terminus of CTB; primers of NcoI-CTB-FW and 
CTB-XhoI-RV were used for the introduction of a His×6 tag on the C-terminus of CTB after the 
gene was inserted in pET28a. So four kinds of ctb genes, which are summarized in Table 3.1, 
were constructed to test what had affected the pentamer formation: His×6 tag, the extra segment 
of amino acids or expression system itself. In the case of the construction of gfp-cta2 fusion gene, 
cta2 was amplified with the primer GFP-CTA2-FW to insert part of gfp sequence. The inserted 
part of gfp sequence is convenient for the linkage with gfp gene to obtain the fusion gene of 
gfp-cta2. The gfp gene was amplified using pEGFP vector as the template. 
 
Table 3.1 Primers and templates used for the construction of ctb and gfp-a2 
Purpose Template  Type Name Sequence* (5’-3’) 
BamHI-CTB-FW actgcggatccacacctcaaaatattactg 
NcoI-CTB-FW cggccatgggtcctcaaaatattactgatt 
His×3-CTB-FW catcatcacacacctcaaaatattactgat 
Forward
NcoI-His×6-CTB-FW cggccatgggtcaccaccaccatcatcacacacct 
CTB-RV-Hind III-2 tggagcaagcttttaatttgccatactaatt  
CTB-BamHI-RV gccggatccttaatttgccatactaattgc 
Construction 
of ctb genes  
CT gene 
Reverse 
CTB-XhoI-RV cggctcgagatttgccatactaattgcggc 
Forward NcoI-GFP-FW gcgccatggtgagcaagggc pEGFP 
vector  Reverse GFP-RV cttgtacagctcgtccatgc 
Forward GFP-CTA2-FW gcatggacgagctgtacaagagtaatacttgcgatgaaaa
Construction 
of genes of 
gfp, cta2 and  
gfp-cta2 
CT gene 
Reverse BamHI-CTA2-RV cgcggatcctcataattcatccttaattct 
*Sequences indicated in bold are sites for restriction enzymes, red nucleotides represent the stop codon, and the 
underlined sequence is the part of gfp gene for the construction of gfp-cta2 fusion gene.  
 
Conditions of PCR reaction for the amplification of genes of ctb, cta2 and gfp were as follows: 
98℃, 5min preheating, followed by 25 cycles of denaturing (98℃, 15sec), annealing (65℃, 
2sec) and elongation (74℃, 30sec). For the ligation of gfp and cta2 genes, PCR reaction 
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conditions were slightly different: PCR products from gfp and cta2 mixed with reaction reagents 
without primers were preheated at 98℃ for 5min, followed by 10 cycles of denaturing (98℃, 
15sec), annealing (65℃, 15sec) and elongation (74℃, 30sec). Then, after the addition of the 
primers of NcoI-GFP-FW and BamHI-CTA2-RV, 25 cycles of denaturing (98℃ , 15sec), 
annealing (65℃, 2sec) and elongation (74℃, 30sec) were performed.  
All primers were purchased from Proligo. PCR was accomplished with high fidelity KOD 
DNA polymerase (Toyobo). After each step of PCR, the product was purified using PCR 
Purification Kit (Qiagen) or purified from the agarose gel (Takara) using Gel Extraction Kit 
(Qiagen). PCR products were analyzed on the 2% agarose gel stained with ethidium bromide by 
electrophoresis.  
 
3.2.3 Construction of recombinant plasmids 
 
Structure and cloning/expression region of E. coli plasmid pET28a is shown in Figure 2.1 of 
Chapter 2, and that of pIVEX2.4d is shown in Figure 3.3. The pIVEX2.4d vector contains all 
regulatory elements necessary for protein expression in RTS E. coli cell-free systems, which are 
based on a combination of T7 RNA polymerase and prokaryotic cell lysates. The vector 
introduces an N-terminal His×6 tag, which allows one-step purification of the protein by 
Ni-NTA affinity chromatography. Moreover, in most cases, His×6 tag (only 0.84kDa) does not 
interfere with the structure of function of the purified protein for a wide variety of proteins.  
In the case of cloning and expression of the ctb gene, the resultant DNA fragments from PCR 
were digested with corresponding restriction enzymes (all purchased from Takara) and cloned 
into pET28a plasmid. After amplified in E. coli JM109, the plasmids were used for the 
expression in the RTS cell-free system or for the transformation in E. coli BL21 (DE3) to obtain 
expressed CTB from E. coli. Restriction sites of ctb gene, and structures and characteristics of 
expressed CTB are shown in Table 3.2. 
In the case of cloning and expression of the gfp-cta2 gene, the resultant DNA fragments from 
PCR were digested with restriction enzymes of NcoI and BamHI. After the digested gene was 
cloned into corresponding sites of pET28a, no expression of protein was found. Therefore, the 
recommended vector of pIVEX2.4d by the RTS E.coli cell-free system was used for expression. 
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After amplification in E. coli XL1 blue, the recombinant plasmid of pIVEX2.4d was used for 
the expression in the cell-free system.  
 
 
 
 
 
Figure 3.3 Structure and cloning/expression region of pIVEX2.4d for the RTS cell-free system  
(https://www.roche-applied-science.com/sis/proteinexpression/index.jsp) 
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Table 3.2 Restriction site of ctb gene, and structure and characteristics of expressed CTB 
 
All the enzymatic digestion products were purified from the agarose gel using Gel Extraction 
Kit, and recombinant plasmids were extracted using Spin Miniprep Kit (Qiagen). Sequences and 
the orientations of inserted genes in recombinant plasmids were analyzed using the method 
described in Materials and methods 2.2.6 of Chapter 2.  
 
3.2.4 Protein expression  
 
3.2.4.1 Expression of CTB in E. coli 
 
CTB (from all of recombinant plasmids of pET28a constructed in the study) was expressed 
in 2ml of LB/kanamycin culture under shaking at 37℃ with the induction of IPTG as 
described in Method and materials 2.2.8.1 of Chapter 2. The cells were pelleted by 
centrifugation, resuspended in 0.5ml 20mM Tris-HCl (pH 8.0) and used for SDS-PAGE 
analysis.  
 
3.2.4.2 Optimal expression time in the RTS cell-free system 
 
Expression of CTB (from pET28a-NcoI-ctb-BamHI) and GFP-CTA2 in the RTS cell-free 
system was performed according to the instruction of RTS 100 E. coli Disulfide Kit (Roche). 
Preparation of working solutions is briefly described in Table 3.3. The recombinant plasmid 
Restriction site of ctb Structure of CTB (N→C) Characteristics of CTB 
BamHI/Hind III His×6-22aa-CTB 
With an N-terminal His×6 tag followed by an 
additional segment of 22 amino acids introduced by the 
recombinant plasmid pET28a 
NcoI/BamHI CTB Nearly the same with the natural CTB 
NcoI/BamHI His×6-CTB With an N-terminal His×6 tag 
NcoI/XhoI CTB-His×6 With a C-terminal His×6 tag 
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(0.5µg in 5µl water) was used as the template for the expression of protein. After rinsed with 
DNase- and RNase-free water, the feeding compartment in the CECF device was filled with 1ml 
of feeding solution, and the reaction compartment with 50µl of reaction solution. All the 
compartments of the device were covered carefully with the adhesive film, then the device was 
inserted into the plastic frame supplied with the kit. The reaction was started by placing the 
frame into the plate shaker (Nissin) setted at 680rpm in the 30℃ incubator. The reaction was 
performed at the different time of 4, 8, 12, 24 or 36h to investigate the optimal expression of 
proteins. The CECF device and the plate shaker are shown in Figure 3.4.  
The expressed CTB was visualized by western blotting using the method described in 
Materials and method 2.2.10 of Chapter 2. The expression of GFP-CTA2 was visualized by 
fluorescence, measured using an ultraviolet transilluminator (Funakoshi) at an excitation 
wavelength of 365nm.  
 
Table 3.3 Preparation of working solutions for protein expression in the RTS cell-free system 
 
 
 
 
 
Solution Component and preparation method (one 50µl reaction ) 
Reaction 
solution 
1. Activated lysate: mix 25µl E. coli lysate and 1µl lysate activator carefully and incubate at 
room temperature for 10-20min 
2. Reaction solution: 7µl reaction mixture, 7µl amino acid mixture, 1µl methionine and 25µl 
activated lysate, 5µl water and 0.5µg of circular DNA template in 5µl water or TE buffer 
Feeding 
solution 
640µl feeding mixture, 140µl amino acid mixture, 20µl methionine and 200µl water  
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 (a)                                      (b) 
Figure 3.4 CECF device and plate shaker for the expression of protein in the RTS cell-free 
system  
(a) CECF device (b) plate shaker 
 
3.2.4.3 Expression of proteins in the RTS cell-free system 
 
Expression of CTB (from all of recombinant plasmids constructed in the study), GFP-CTA2, 
and coexpression of GFP-CTA2 and CTB (from pET28a-NcoI-ctb-BamHI) were performed 
according to the method described above with the reaction time of 24h. The plasmid 
pIVEX2.3-GFP WT (wild type GFP) supplied by the kit was expressed as the positive control at 
the same time.  
 
3.2.5 Investigation of the formation of CTB pentamer 
 
3.2.5.1 Western blotting  
 
Reaction compartment  
Semipermeable membrane 
Feeding compartment 
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To visualize the pentameric CTB, protein samples were treated before applied on SDS-PAGE 
using the method different from that described in Materials and methods 2.2.9 of Chaper 2. No 
mercaptoethanol (a reductant for the disulfide bond) was added in 2×sample buffer, and samples 
were not treated with heat. The preparation method of SDS-PAGE, buffer compositions and 
electrophoretic conditions were the same with those described before.  
After the electrophoresis, the visualization of pentameric CTB was performed by western 
blotting using the method described before, except that only the anti-cholera toxin antibody was 
used as the primary antibody for the detection.  
 
3.2.5.2 GM1-ganglioside binding assay  
 
GM1-ELISA was performed to detect the GM1-ganglioside binding activity of CTB 
synthesized in the RTS cell-free system. The 96-well microtiter plate (Nunc, maxisoap type) 
was coated with GM1-monosialoganglioside (Sigma) by incubating the plate with 50µl/well of 
GM1 methanol solution (0.2µg/ml) in vacuum desiccator at room temperature overnight. The 
plate was blocked by incubation in the blocking buffer (1% BSA/PBS, 100µl/well) for 30min at 
25℃, and the blocking buffer was removed by flicking the plate on the absorbant paper. Serial 
dilutions (50, 25, 12.5, 6.25 and 3.125ng/well) of commercial CTB, CTB (from 
pET28a-NcoI-ctb-BamHI and pET28a-NcoI-ctb-XhoI-His×6) expressed in the RTS cell-free 
system (500-, 1000- and 2000-times diluted) and negative control (only buffer) were loaded in 
the wells (50µl/well) and incubated for 30min at 25℃. Subsequently, the plate was incubated in 
the rabbit anti-cholera toxin primary antibody (Sigma) in the washing buffer (1:5000 dilution, 
50µl/well) at 25℃ for 45min, followed by incubation with the anti-rabbit IgG-HRP secondary 
antibody (Amersham) in washing buffer (1:5000 dilutioin, 50µl/well) for 30min at 25℃. After 
each incubation step, the plate was washed fully (three or four times) with the washing buffer 
(200µl/well), ensuring complete elimination of nonspecific absorption of antibody. Finally, the 
chromogenic substrate of ABTS (2,2’-Azino-Bis (3-ethylbenzthiazoline-6-sulfonic Acid)) 
(Sigma) (50µl/well) was added and the plate was incubated at 25℃ for 5, 10, 15, 20, 30 and 
40min, respectively, to develop the color. Absorbances were measured in the microplate reader 
at 405nm.  
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Linear standard curve of absorbances versus the known concentrations of commercial CTB, 
was established. The expression levels of pentameric CTB in the RTS cell-free system were 
estimated by comparing the absorbances with the standard curve.  
 
3.2.6 Investigation of the formation of holotoxin-like complex of GFP-CTA2 and CTB 
 
3.2.6.1 Purification of coexpressed GFP-CTA2 and CTB 
 
To investigate the formation of holotoxin-like complex of GFP-CTA2 and CTB, purification 
of coexpressed GFP-CTA2 and CTB was performed. Because GFP-CTA2 has a His×6 tag on its 
N terminus, CTB without His×6 tag (from pET28a-NcoI-ctb-BamHI) will be purified together 
if the complex of GFP-CTA2 and CTB forms. The purification of mixture of GFP-CTA2 and 
CTB was also performed as the control.  
The purification was done according to the instruction of QIAexpress Type IV Kit (Qiagen) 
under native conditions with some modifications. Buffers used in the purification are listed in 
Table 3.4. The pooled solution from four reactions (about 200µl) was mixed with 800µl of the 
lysis buffer to give a 1ml solution. After incubated with 0.25ml of 50% Ni-NTA resin by gentle 
shaking at 4℃ for 60min, the mixture was loaded into a column to collect the flow-through. 
The resin was washed twice with the wash buffer (1ml/time), followed by elution with the 
elution buffer I (0.125ml/time, four times), the elution buffer II (0.125ml/time, four times) and 
the elution buffer III (0.125ml/time, four times), respectively.  
Samples were concentrated to the appropriate volume by centrifugal filter devices (Amicon 
Ultra-4, 5000 MWCO, Millipore) and detected by western blotting using anti-cholera toxin 
antibody as the primary antibody.  
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Table 3.4 Buffers used for the purification of proteins expressed in the RTS cell-free system 
Buffer Composition pH 
Lysis buffer  50mM NaH2PO4, 300mM NaCl  8 
Wash buffer 50mM NaH2PO4, 300mM NaCl, 5mM imidazole  8 
Elution buffer I  50mM NaH2PO4, 300mM NaCl, 20mM imidazole  8 
Elution buffer II  50mM NaH2PO4, 300mM NaCl, 100mM imidazole  8 
Elution buffer III 50mM NaH2PO4, 300mM NaCl, 250mM imidazole 8 
 
3.2.6.2 SDS-PAGE 
 
To visualize the fluorescent GFP-CTA2, and if possible, the complex of GFP-CTA2 and 
pentameric CTB on SDS-PAGE, protein samples were treated using the method as described 
above: no mercaptoethanol was added in 2×sample buffer, and samples were not treated with 
heat. The preparation method of SDS-PAGE, buffer compositions and electrophoretic conditions 
were also the same with those described before. After the electrophoresis, the fluorescence was 
visualized by putting the gel in an ultraviolet transilluminator with an excitation wavelength of 
365nm.  
 
3.2.6.3 Western blotting   
 
To understand the actual molecular weight of GFP-CTA2, protein samples were treated with 
heat and mercaptoethanol before loaded on SDS-PAGE. Western blotting was performed 
according to the method described before, except that anti-rabbit polyclonal GFP antiserum 
(Invitrogen) was used as the primary antibody.  
To investigate the formation of complex of GFP-CTA2 and CTB, samples in the purification 
were treated with heat and mercaptoethanol and applied for western blotting detection. 
Anti-cholera toxin antibody was used as the primary antibody.  
 
3.3 Results and discussion 
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3.3.1 Construction of genes and recombinant plasmids 
 
Sizes of resultant PCR products (BamHI-ctb-Hind III not shown) visualized on the agarose 
gel (Figure 3.5) are in good agreement with the calculated ones shown in Table 3.5.  
 
 
 
 
 
 
 
                        (a)                         (b) 
Figure 3.5 Electrophoretic analysis of PCR products  
(a) PCR products for the construction of ctb genes. Lane 1, 200 bp marker; Lane 2, NcoI-ctb-BamHI; 
Lane 3, NcoI -his×6-ctb-BamHI; Lane 4, NcoI-ctb-XhoI-his×6. (b) PCR products for the 
construction of GFP-CTA2 gene. Lane 1, 200bp marker; Lane 2, NcoI-gfp; Lane 3, gfp*-cta2-BamHI 
(*part of gfp gene (20bp)); Lane 4, NcoI-gfp-cta2-BamHI.  
 
Table 3.5 Calculated sizes of PCR products 
PCR product Size (bp) 
BamHI-ctb-Hind III 332 
NcoI-ctb-BamHI 329 
NcoI-his×6-ctb-BamHI 347 
NcoI-ctb-XhoI-his×6  327 
NcoI-gfp 726 
gfp*-cta2-BamHI 161 
NcoI-gfp-cta2-BamHI 861 
*part of gfp gene (20bp).  
 
1   2   3   4 1   2   3    4 
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PCR products were cloned into the expression plasmid of pET28a or pIVEX2.4d. Results of 
sequencing analysis showed that sequences were identical to the designed ones and had correct 
orientations in expression plasmids.  
Sequences of nucleotide and amino acid of CTB are shown in Figure 2.5, and those of 
GFP-CTA2 are shown in Figure 3.6. 
 
DNA sequence of GFP-CTA2  
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGT
AAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGA
AGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCG
TGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAG
GCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGT
TCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATC
CTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC
GGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCC
GCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGG
GATCACTCTCGGCATGGACGAGCTGTACAAG—AGTAATACTTGCGATGAAAAAACCCAAAGTCTAGGTGTAA
AATTCCTTGACGAATACCAATCTAAAGTTAAAAGACAAATATTTTCAGGCTATCAATCTGATATTGATACACATAATA
GAATTAAGGATGAATTA 
 
Amino acid sequence of GFP-CTA2 
MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCF
SRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEK
RDHMVLLEFVTAAGITLGMDELYK--SNTCDEKTQSLGVKFLDEYQSKVKRQIFSGYQSDIDTHNRIKDEL 
 
Figure 3.6 Sequences of nucleotide and amino acid of GFP-CTA2  
(Italic parts are the sequences of CTA2) 
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3.3.2 Optimal expression time in the RTS cell-free system 
 
Time-courses of CTB and GFP-CTA2 expression in the RTS cell-free system are shown in 
Figure 3.7. Results showed that the expressed quantity of CTB or GFP-CTA2 was increased 
with the increase in the expression time, and the expression maximized at the time of 24h. So 
the time of 24h was used as the optimal expression time hereafter. 
 
    
(a) 
 
  
(b) 
Figure 3.7 Time-course of protein expression in the RTS cell-free system 
(a) Time-course of CTB expression (visualized by western blotting). Lane 1, CTB expressed for 4h; 
Lane 2, CTB expressed for 8h; Lane 3, CTB expressed for 12h; Lane 4, CTB expressed for 24h; 
Lane 5, CTB expressed for 36h. 5µl samples were applied. (b) Time-course of GFP-CTA2 expression 
(visualized by fluorescence). Tube 1, GFP-CTA2 expressed for 4h; Tube 2, GFP-CTA2 expressed for 
8h; Tube 3, GFP-CTA2 expressed for 12h; Tube 4, GFP-CTA2 expressed for 24h; Tube 5, GFP-CTA2 
expressed for 36h.  
 
3.3.3 Expression of pentamer CTB  
 
3.3.3.1 Comparison of pentameric CTB expressed in E. coli and in the RTS cell-free system 
 
It was found that the pentamer of commercial CTB was retained on SDS-PAGE after the 
treatment with SDS. Under the strict treatments with mercaptoethanol and heating at 90℃ for 
5min, the pentamer of commercial CTB was separated into monomer.  
Results in Figure 3.8 showed that nearly no pentameric CTB was visible by western blotting 
１  2    3    4    5   
１     2        3        4        5  
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when expressed in E. coli. Even in the case of expression of CTB possessing nearly the same 
structure with the natural one, the formation of pentamer was still difficult. This indicated that E. 
coli expression system should be, at least mainly, responsible for the poor formation of pentamer. 
Moreover, the dimer or trimer was very difficult to separate even with the treatments of 
mercaptoethanol and heating at 90℃ for 5min, which keeps unknown to our knowledge.  
Figure 3.9 showed CTB expressed in the RTS cell-free system. In the expression of CTB and 
CTB-His×6, pentamers were formed steadily and completely. Even in the expression of 
His×6-22aa-CTB, at least half of the protein formed the pentamer.  
 
 
Figure 3.8 CTB expressed in E. coli (detected by western blotting) 
Lane 1, Commercial CTB (+); Lane 2, Commercial CTB (-); Lane 3, His×6-22aa-CTB (+); Lane 4, 
His×6-22aa-CTB (-); Lane 5, CTB (+); Lane 6, CTB (-); Lane 7, His×6-CTB (+); Lane 8, 
His×6-CTB (-); Lane 9, CTB-His×6 (+); Lane 10, CTB-His×6 (-). Arrows indicated monomer or 
multimer of CTB. m, monomer; d, dimer; t, trimer; p, pentamer.  
+, Samples were mixed in the sample buffer (two times concentrated) containing 12% 
β-mercaptoethanol as well as treated with heat at 90℃ for 5min. -, Samples were mixed in the 
2×sample buffer without the addition of β-mercaptoethanol, and were not heated.  
 
The formation of multimeric CTB expressed in E. coli and the RTS cell-free system is 
summarized in Table 3.6. It can be concluded that the RTS cell-free system expressed 
pentameric CTB successfully.  
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Figure 3.9 CTB expressed in the RTS cell-free system (detected by western blotting) 
Lane 1, Commercial CTB (-); Lane 2, His×6-22aa-CTB (-); Lane 3, CTB (+); Lane 4, CTB (-); 
Lane 5, CTB-His×6 (+); Lane 6, CTB-His×6 (-). Arrows indicated monomer or multimer of CTB. 
m, monomer; p, pentamer. +, Samples were mixed in the sample buffer (two times concentrated) 
containing 12% β-mercaptoethanol as well as treated with heat at 90℃ for 5min. -, Samples were 
mixed in the 2×sample buffer without the addition of β-mercaptoethanol, and were not heated.  
 
Table 3.6 Comparison of CTB expressed in E. coli and the RTS cell-free system 
+, Samples were mixed in the 2×sample buffer containing 12% β-mercaptoethanol as well as treated with heat at 90
℃ for 5min. -, Samples were mixed in the 2×sample buffer without the addition of β-mercaptoethanol, and were not 
heated.  
 
3.3.3.2 Further verification of pentameric CTB expressed in the RTS cell-free system by 
GM1-ELISA  
Expressed CTB  CTB structure 
(N→C) 
Theoretical MW 
(kDa) 
Sample treatment
E. coli RTS cell-free system 
+ monomer~trimer not determined 
His×6-22aa-CTB 15 
- monomer~trimer monomer and pentamer 
+ monomer~trimer monomer 
CTB 11.6 
- monomer~trimer pentamer 
+ monomer~trimer not determined 
His×6-CTB 12.5 
- monomer~trimer not determined 
+ monomer~dimer monomer 
CTB-His×6 12.5 
- monomer~dimer pentamer 
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The linear relationship between the absorbance and the concentration of CTB is shown in 
Figure 3.10. The expression level of pentameric CTB in the RTS cell-free system is shown in 
Table 3.7.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Linear relationship of absorbance versus concentration of CTB at the different color 
developing time  
 
Table 3.7 Concentration measurement of pentameric CTB expressed in the RTS cell-free system 
Concentration (ng/ml) determined at different color developing time  
Sample 
Dilution 
times 5 min 10min 16min 20min 30min 40min 
Mean 
concentration
(µg/µl) 
2000× 49 38 39 40 39 37 
3000× 44 35 36 38 37 38 
4000× 37 31 31 34 35 37 
CTB 
6000× 32 28 28 30 31 32 
0.128 
2000× 33 29 30 32 32 33 
3000× 30 28 30 32 33 35 
4000× 31 27 28 30 32 34 
CTB-His×6 
6000× 23 26 25 25 28 32 
0.109 
y = 0.0041x + 0.0231
R2 = 0.9969
y = 0.008x + 0.0288
R2 = 0.9982
y = 0.0114x + 0.0581
R2 = 0.9951
y = 0.0131x + 0.0534
R2 = 0.9883 y = 0.0107x + 0.0465
R2 = 0.9969
y = 0.0129x + 0.0627
R2 = 0.991
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 10 20 30 40 50 60
CTB concentration (ng/ml)
A
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Ratio of pentameric CTB or CTB-His×6 expressed in the RTS cell-free system was estimated 
by comparison with known concentrations of commercial CTB. The result of western blotting is 
shown in Figure 3.11. It was estimated that the bands of CTB and CTB-His×6 expressed in the 
RTS cell-free system were the same or larger than the band with 0.5µg of commercial CTB. 
Because 5µl of sample was applied, concentrations of these CTB are equivalent to or larger than 
0.1µg/µl. Compared with the result from GM1-ELISA, the conclusion can be drawn that nearly 
100% of CTB expressed in the RTS cell-free system formed pentamer.  
 
 
 
Figure 3.11 Ratio estimation of pentameric CTB expressed in the RTS cell-free system (detected 
by western blotting) 
Lane 1, 0.1µg commercial CTB; Lane 2, 0.2µg commercial CTB; Lane 3, 0.3µg commercial CTB; 
Lane 4, 0.4µg commercial CTB; Lane 5, 0.5µg commercial CTB; Lane 6, CTB expressed in the RTS 
cell-free system (5µl); Lane 7, CTB-His×6 expressed in the RTS cell-free system (5µl). Samples 
were mixed in the 2×sample buffer containing 12% β-mercaptoethanol as well as treated with heat at 
90℃ for 5min before loaded on SDS-PAGE.  
 
According to the result obtained in our laboratory before [43], only 0.6% of His×6-22aa-CTB 
expressed in E. coli formed pentamer. But in the RTS cell-free system, CTB pentamer formed 
easily and completely. It indicates that the cell-free system has the superior ability in expressing 
properly folded proteins, suggesting its potential applications in characterization studies, 
structural and functional assays of proteins.   
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3.3.4 Investigation of the formation of holotoxin-like complex of GFP-CTA2 and CTB 
 
  
(a)                                         (b) 
Figure 3.12 Purification of co-expressed and mixed GFP-CTA2 and CTB 
(a) Co-expressed GFP-CTA2 and CTB (b) Mixed GFP-CTA2 and CTB. Lane 1, CTB expressed in 
the cell-free system; Lane 2, Co-expressed or mixed GFP-CTA2 and CTB; Lane 3, Flow-through 
(pooled, 20×concentrated); Lane 4, Washed fraction (pooled, 33×concentrated); Lane 5, Eluted 
fraction I (pooled, 8×concentrated); Lane 6, Eluted fraction II (the first eluted fraction, 
2×concentrated); Lane 7, Eluted fraction II (the second eluted fraction, 2×concentrated); Lane 8, 
Eluted fraction II (the third eluted fraction, 2.5×concentrated); Lane 9, Eluted fraction II (the fourth 
eluted fraction, 2.5×concentrated); Lane 10, Eluted fraction III (pooled, 10×concentrated). Five µl 
protein samples were applied on SDS-PAGE. 
 
It should be noticed that the mixture of GFP-CTA2 and CTB cannot form the complex 
because CTA2 only associates with the intermediate of CTB, but not the assembled CTB 
pentamer. Therefore, from the results shown in Figure 3.12, in spite of the detection of CTB in 
the purified fractions, nearly the same results were obtained from co-expression and mixture of 
GFP-CTA2 and CTB. This indicated that the detected CTB was the nonspecifically absorbed 
one on the affinity column but not from the formed complex.  
It was found that the fluorescence of GFP-CTA2 was retained on SDS-PAGE after the 
treatment with SDS. When treated with mercaptoethanol and heating, the fluorescence of 
GFP-CTA2 was lost.  
GFP-CTA2 visualized by fluorescence on SDS-PAGE and western blotting is shown in Figure 
3.13. It was seen that GFP-CTA2 was expressed as at least two products, which might be due to 
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the degradation or incomplete expression of protein. The expressed GFP-CTA2 at different 
reaction time also had two bands on fluorescent SDS-PAGE (data not shown), which indicated 
the degradation or incomplete expression happened in the expression process, and was 
time-independent. The addition of protease inhibitor was not workable (data not shown).  
 
            
(a)                     (b) 
Figure 3.13 Visualization of GFP-CTA2 expressed in the RTS cell-free system 
(a) Visualized by fluorescence on SDS-PAGE (b) Visualized by western blotting. Lane 1, Positive 
control GFP (wild type); Lane 2, GFP-CTA2; Lane 3, Mixture of GFP-CTA2 and CTB; Lane 4, 
Coexpression of GFP-CTA2 and CTB. 
 
In theory, GFP-CTA2 (expressed from pIVEX2.4d, 35kDa) should have a higher molecular 
weight than that of positive control GFP (wild type, 28kDa). When they were treated with heat 
and mercaptoethanol, it was the case (Figure 3.13b). However, actually GFP-CTA2 showed a 
lower apparent molecular weight than that of GFP on SDS-PAGE when both of them were not 
treated with mercaptoethanol and heating (Figure 3.13a). This indicated that the compact 
structure of GFP-CTA2 might be due to the interaction between the segments of GFP and CTA2.  
There are some assumptions about the failure in the formation of holotoxin-like complex 
between GFP-CTA2 and CTB. These are: (1) Degradation or incomplete expression of 
GFP-CTA2 made no complete CTA2 available; (2) Hydrophobic region inside the cylindrical 
structure (shown in Figure 3.14) of GFP buried the hydrophobic CTA2; (3) Some chaperons 
function to facilitate and/or stabilize the formation of complex. To solve the problems, more 
stable and/or more hydrophilic model protein instead of GFP, or a flexible linker between GFP 
and CTA2 is expected to be workable. Also, the functional chaperons have to be investigated.  
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Figure 3.14 Molecular structure of green fluorescence protein. 
Eleven strands of β-sheet (green) form the walls of a cylinder, and short segments of α-helices (blue) 
cap the top and bottom of the can and also provide a scaffold for the fluorophore which is near 
geometric center of the can. (from http://www-bioc.rice.edu/Bioch/Phillips/Papers/gfpbio.html) 
 
3.4 Summary 
 
Pentameric CTB was little expressed in E. coli, but expressed in the RTS cell-free system 
steadily and completely. This indicated that the cell-free system was a valuable tool and 
platform for the expression of structurally complex oligomeric proteins.  
An attempt to assemble cholera toxin-like complex by coexpressing GFP-CTA2 and CTB in 
the RTS cell-free system was done. Results revealed no formation of complex. More stable 
and/or more hydrophilic model protein instead of GFP, or a flexible linker between GFP and 
CTA2 is expected to be workable for the formation of complex.  
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Appendix 
 
I Abbreviations 
 
CT cholera toxin 
CTB cholera toxin B subunit 
CTA cholera toxin A subunit 
Cry j Allergen protein from the pollen of Cryptomeria japonica 
GFP green fluorescent protein 
BSA bovine serum albumin 
IgE immunoglobulin E 
MHC major histocompatibility complex 
HLA human leukocyte antigens 
DNA deoxyribonucleic acid 
PCR polymerase chain reaction 
FW  forward  
RV  reverse 
aa amino acid 
E. coli Escherichia coli 
B. subtilis Bacillus subtilis 
RBS ribosome-binding site 
ORF open reading frame 
T-vector T-extended vector 
LB Luria-Bertani  
IPTG isopropyl-β-D-thiogalactopyranoside 
X-gal 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside 
Amp ampicillin 
Cm chloramphenicol 
 II
 
 
 
 
 
 
 
 
 
Kana kanamycin 
Tc tetracycline 
Bs blasticidin S 
Tris tris (hydroxymethyl) aminomethane 
PBS phosphate buffered saline 
His×6  hexahistidine  
TCA trichloroacetic acid 
Ni-NTA   nickel-nitrilotriacetic acid 
SDS sodium dodecyl sulfate 
APS ammonium persulfate 
TEMED N’N’-bis-methylene-acrylamide 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
PVDF polyvinylidene difluoride 
ELISA   enzyme-linked immunosorbent assay 
kDa kilodalton 
RTS rapid translation system 
CECF continuous exchange cell-free  
 III
II Reagents preparation 
 
1. DNA operation 
 
a. 10×TAE Buffer 
Tris  48.4g 
Acetic acid 11ml 
EDTA solution (0.25M) 40ml 
Distilled water to 1000ml (adjusted to pH 7.8) 
 
b. 5×TBE Buffer 
Tris 54g 
Boric acid 27.5g 
EDTA・2Na 3.7g 
Distilled water to 1000ml 
 
c. TE Buffer 
Tris  10mM 
EDTA  1mM (pH 8.0) 
 
 
2. Bacterial cultivation and protein expression 
 
a. LB medium 
Tryptone 10g 
Yeast Extract 5g 
NaCl 10g 
Agar 15g (for liquid medium, agar is not needed) 
Distilled water to 1000ml (adjusted to pH 7.2 and autoclaved) 
 IV
b. 2M Mg solution (1M MgCl2/1M MgSO4, filter-sterilized) 
MgCl2・6H2O 2.033g 
MgSO4・7H2O 2.4648g 
Distilled water to 10ml  
 
c. SOB medium 
Tryptone 20g  
Yeast extract 5g  
NaCl 0.585g  
KCl 0.186g  
Distilled water to 1000ml 
(autoclaved and cooled to the 
room temperature before the 
addition of 2M Mg solution) 
2M Mg solution  10ml  
 
d. SOC medium 
SOB medium 1000ml 
glucose solution (2M) 10ml (filter-sterilized and stored at 4℃) 
 
e. Ampicillin stock solution (100mg/ml, stored at -20℃) 
Ampicillin sodium 5g 
Distilled water to 50ml 
 
f. Kanamycin stock solution (25mg/ml, stored at -20℃) 
Kanamycin sulfate 1.25g 
Distilled water to 50ml 
 
g. Tetracycline stock solution (5mg/ml, stored at -20℃ and protected from light) 
Tetracycline hydrochloride 0.25g 
Ethanol  to 50ml 
 
 V
h. Chloramphenicol stock solution (5mg/ml, stored at -20℃ and protected from light)  
Chloramphenicol  0.25g 
Ethanol to 50ml 
 
i. Blasticidin S stock solution (250mg/ml, stored at -20℃) 
Blasticidin S hydrochloride 25mg 
Distilled water to 100µl 
 
j. IPTG stock solution (100mM, stored at -20℃) 
IPTG 23.8mg 
Distilled water to 1ml 
 
k. X-gal stock solution (40mg/ml, stored at -20℃ and protected from light) 
X-gal  400mg 
Dimethylformamide to 10ml  
 
 
3. Protein separation (SDS-PAGE) 
 
a. Acrylamide/bis solution (30%, stored at 4℃ and protected from light) 
Acrylamide 29.2g 
TEMED 0.8g 
Distilled water to 100ml 
 
b. 1.5M Tris-HCl buffer (pH 8.8, stored at 4℃) 
Tris 18.15g 
Distilled water to 100ml 
 
 
 VI
c. 0.5M Tris-HCl buffer (pH 6.8, stored at 4℃) 
Tris  6g 
Distilled water to 100ml 
 
d. SDS solution (10%, stored at room temperature) 
SDS (sodium dodecyl sulfate) 10g 
Distilled water to 100ml 
 
e. APS solution (10%, freshly prepared) 
 
APS  0.1g 
Distilled water 1ml 
 
f. 2×sample buffer 
0.5M Tris-HCl buffer (pH 6.8) 2ml 
SDS solution (10%) 4ml 
β-mercaptoethanol 1.2ml 
Glycerol 2ml 
Distilled water  0.8ml 
Bromophenol blue solution (1%) some drops 
  
g. 5×electrode buffer (pH 8.3) 
Tris  15g 
Glycine 72g 
SDS 5g 
Distilled water to 1000ml 
 
 
 
 
 VII
h. Destaining solution 
Methanol 1200ml 
Acetic acid 300ml 
Distilled water 1500ml 
 
i. Staining solution (0.1%) 
Coomassie Blue R-250 0.3g 
Destaining solution to 300ml 
 
 
4. Immunodetection of protein (western blotting) 
 
a. Blotting buffer 
Tris 12g 
Glycine 14.4g 
Distilled water 800ml 
Methanol 200ml 
 
b. 10×PBS buffer (stored at 4℃) 
NaCl 80g 
Na2HPO4・12H2O  
(or Na2HPO4・7H2O  
or anhydrous Na2HPO4) 
29g 
(or 22g or 11g) 
KCl 2g 
KH2PO4 2g 
Distilled water to 1000ml 
 
 
 
 VIII
c. Blocking buffer (1%) 
Milk powder 0.5g 
1×PBS buffer to 50ml 
 
d. PBS-T buffer (0.5%) 
Tween 20 5g 
1×PBS buffer to 1000ml 
 
 
5. Immunodetection of protein (ELISA) 
 
a. GM1-ganglioside stock solution (20µg/ml, stored at -20℃) 
GM1-ganglioside  1mg 
Methanol  to 50ml 
 
b. BSA/PBS stock solution (10%, stored at 4℃) 
BSA 5g  
Distilled water 45ml 
10×PBS buffer 5ml  
(dissolved at 50℃, 0.22µm-filtrated)  
 
c. Blocking buffer (1%) 
BSA/PBS stock solution (10%) 1ml 
1×PBS buffer 9ml 
 
d. Washing buffer  
Tween 20 0.25g 
10×PBS buffer 49.5ml           ①:②=99:1 
Distilled water to 495ml  
BSA/PBS stock solution (10%) 5ml        
  
 
①
 
 
② 
